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Developments in Synthetic Biology
Are Altering the IP Imperatives of
Biotechnology
ChristopherM. Holman*
ABSTRACT
While the accomplishments of the biotechnology industry have
been substantial, recent technological advances promise to
dramatically increase the power and utility of the discipline over the
coming years. The term "synthetic biology" has been coined to describe
the application of these powerful new tools to the engineering of
synthetic genetic sequences and organisms. In essence, synthetic
biology represents the next iteration in the ongoing evolution of
biotechnology, and hopes run high that in time, the fruits of synthetic
biology will dwarf the past successes of conventional biotechnology.
There is, however, some concern that the current patent-centric
approach to Intellectual Property (IP), which has for years been the
norm in biotechnology, is ill-suited for the needs of synthetic biologists
and synthetic biology companies. This Article addresses these concerns
and considers potential modifications to the IP system that might
render it better suited to promote progress in synthetic biology. The
Article begins with an overview of conventional biotechnology,
including a discussion of the critical role IP has played in the growth
and development of the conventional biotechnology industry. Next it
describes the ongoing synthetic biology revolution, as illustrated by
specific examples of various types of synthetic biology companies and
user-innovators. The Article then explores the emerging IP imperatives
of synthetic biology, highlighting numerous deficiencies under the
current IP regime. It concludes with suggestions for adaptingIP to the
imperatives of synthetic biology, including a proposal to enlist
copyright in the protectionof synthetic biology innovations.

Professor of Law, University of Missouri-Kansas City School of Law. The author
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I. INTRODUCTION
In less than forty years, biotechnology has progressed from the
hopes and aspirations of a few academic scientists and venture
capitalists to become a leading technological sector of the economy.
Biotechnology companies have successfully applied the foundational
tools of genetic engineering to the production of innovative products,
primarily in the realm of pharmaceuticals and agriculture, which have
provided important benefits to human health and the environment.
While the accomplishments of biotechnology have been substantial,
more recent technological advances promise to dramatically increase
the power and utility of the discipline over the coming years. In
recent years, the term "synthetic biology" has been coined to describe
the application of these powerful new tools to the engineering of
synthetic genetic sequences and organisms.
In essence, synthetic
biology represents the next iteration in the ongoing evolution of
biotechnology, and hopes run high that in time, the fruits of synthetic
biology will dwarf the past successes of conventional biotechnology.
At a recent "Intellectual Property Law and the Biosciences
Conference" at Stanford University, Drew Endy, a Professor of
Bioengineering at Stanford and vocal thought leader in the field of
synthetic biology, opined that "property rights" will be a significant
rate-limiting factor in the advance of synthetic biology.' This is ironic,
in that conventional wisdom has long held that the availability of
strong intellectual property (IP) protection has played a critical role in
the success of the current biotechnology industry.
During his
presentation, Professor Endy bemoaned what he views as the lack of a
vibrant "public domain" in genetic engineering, and the difficulty
patents pose for synthetic biology companies attempting to develop
products without incurring potentially crushing liability for patent
infringement. 2 He implored the audience, largely composed of IP
lawyers and law professors, to "please make that easier." 3 Endy noted
that while a number of important biotechnology patent cases were
working their way through the courts, to his knowledge, none of them
would address the critical issues raised by advances in synthetic
biology, such as the fungibility of genetic information and genetic
material, the geometric increase in the scale and complexity of genetic

1.
Drew Endy, Professor, Stanford Univ., Keynote Address at the Stanford Law School
Conference on Intellectual Property Law and the Biosciences 3:20 (Apr. 27, 2012),
http://www.youtube.com/watch?v=Qku30Q5OU4.
2.
Id. at 3:00, 43:40.
3.
Id. at 43:40.
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engineering projects, and the trend toward specialization and division
of labor in synthetic biology.4
Professor Endy is not alone in his thinking. Many leaders and
commentators in the field of synthetic biology share his concern that
the current patent-centric approach to IP, which has for years been
the norm in biotechnology, is ill-suited for the needs of synthetic
biologists and synthetic biology companies. 5 This Article addresses
these concerns and considers potential modifications to the IP system
that might render it better suited to promote progress in synthetic
biology.
The Article begins in Part II with an overview of conventional
biotechnology, focusing on its origins and the backstories of some
Part III
representative conventional biotechnology companies.
and
growth
the
in
has
played
IP
role
discusses the critical
Part IV
development of the conventional biotechnology industry.
describes the ongoing synthetic biology revolution, as illustrated by
specific examples of various types of synthetic biology companies and
user-innovators. Part V explores the emerging IP imperatives of
synthetic biology, highlighting numerous deficiencies under the
current IP regime. Part VI provides suggestions for adapting IP to the
imperatives of synthetic biology, and Part VII proposes a role for
copyright in the protection of synthetic biology innovations.
II. CONVENTIONAL BIOTECHNOLOGY
In order to better understand the distinction made in this
Article between "conventional biotechnology" and "synthetic biology,"
let us begin by briefly reviewing the history of conventional
biotechnology and the origins of some representative conventional
biotechnology companies. The seminal breakthrough that gave birth
to conventional biotechnology was the development of techniques for
selectively recombining DNA molecules, first reported in 1973 by
Stanley Cohen of Stanford University and Herbert Boyer of the
University of California, San Francisco. 6 Around the same time,
methodologies were being refined elsewhere for introducing the
resulting recombinant DNA molecules into living cells. Armed with
these powerful tools, a conventional biotechnologist could assemble a
recombinant DNA molecule comprising a genetic sequence encoding a
Id. at 42:20.
4.
See, e.g., Arti Rai & James Boyle, Synthetic Biology: Caught Between Property
5.
Rights, the Public Domain, and the Commons, 5 PLOS BIOLOGY 0389 (2007).
6.

BIOTECHNOLOGY INDUS.

Blake & Debbie Strickland
files/BiotechGuide2008.pdf.

eds.,

ORG., GUIDE TO BIOTECHNOLOGY 2 (Roxanna Guilford-

2008),

available at

http://www.bio.org/sites/default/
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protein of interest-i.e., in the vernacular, a gene-combined with

various genetic regulatory elements and introduce the recombinant
DNA molecule into a living organism, usually a single celled microbe,
thereby causing the organism to produce large quantities of the
protein encoded by the non-native gene.
In a typical application of conventional biotechnology, the
recombinant DNA introduced into the organism causes it to express a
protein that is not normally produced by the unmodified host
organism-or at least to express much larger quantities of a protein
that is normally produced by the organism.7 In many instances, the
ultimate commercial product is the recombinantly expressed protein,
as in the case of a human protein produced in cultured microbial cells
and purified for use as a biologic drug. In other cases, the commercial
product is the entire recombinant organism, as in the case of a crop
plant, or its seed, modified by the introduction of a gene encoding a
pesticidal protein.
The products of conventional biotechnology
generally tend to involve the recombinant expression of a single,
naturally occurring gene, which, as discussed below, is an important
point of distinction between conventional biotechnology and synthetic
biology.
A. Case Studies of PioneeringConventional Biotechnology Companies
Genentech, Amgen, and Monsanto were three pioneers in the
commercialization of biotechnology, and today they stand among the
largest and most successful biotechnology companies. This Section
briefly summarizes the corporate histories of these biotechnology
legends. As case studies, the histories serve to illustrate many of the
fundamental characteristics that have come to define the business
paradigm of conventional biotechnology companies and to distinguish
conventional biotechnology from synthetic biology. Also considered
are two lesser-known but nonetheless pioneering biotechnology
companies-Calgene and Genencor-whose histories exemplify the
diversity that has existed within conventional biotechnology since its
earliest days.
Genentech, Inc., generally recognized as the first commercially
successful biotechnology company, was founded in 1976 by venture
capitalist Robert Swanson and biochemist Herbert Boyer, mentioned

7.
See DANIEL CHARLES, LORDS OF THE HARVEST: BIOTECH, BIG MONEY, AND THE
FUTURE OF FOOD 299-300 (2008) (describing how the first wave of successful biotechnology
companies, including Genentech and Amgen, made their money by producing valuable human
proteins in cultured bacterial cells).
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above as one of the inventors of recombinant DNA technology.8 In
1980, the company sold one million shares of stock in an initial public
offering at $35 per share. 9 Before the day ended, shares traded for as
high as $89, evidencing the investing public's enthusiasm for the new
technology and its anticipation of huge profits to come. 10
Genentech's approach to product development initially focused
on introducing human genes into microorganisms in order to produce
recombinant human proteins to be used as replacement therapy
drugs. In 1977, Genentech scientists achieved a notable triumph by
being
first
the
to
produce
a
human
protein
in
a
microorganism-somatostatin in E. coli bacteria."
The company
succeeded in cloning the human insulin gene in 1978, and promptly
licensed the production and commercialization of recombinant insulin
to Eli Lilly and Company. 12 The US Food and Drug Administration
(FDA) approved the marketing of recombinant insulin for use as a
drug in 1982, making it the first biotechnology product to achieve
significant commercial success. 13
The recombinant production of human insulin represented a
landmark achievement.
Prior to Genentech's application of
conventional biotechnology to the problem, native human insulin
derived from a human source could only be obtained in minute
quantities-sufficient for the demands of basic research but
inadequate for general pharmaceutical use. 14 Patients in need of
insulin therapy were forced to resort to the use of porcine (pig) insulin,
a molecule that is structurally similar but not identical to human
insulin.1"
Cloning the human insulin gene and expressing it in
bacteria not only opened the door to the production of virtually
unlimited quantities of clinically superior human insulin, but by
producing the insulin in cultured bacteria, Genentech was able to
avoid toxins that can contaminate native proteins derived from animal
sources.
In 1985, Genentech received FDA approval to market
recombinant human growth hormone (hGH) for the treatment of

8.
A
History of
Firsts,
GENENTECH,
information/chronology (last visited Jan. 29, 2013).
9.

Genentech

IPO,

LIFE

SCIENCES

http://www.gene.com/media/company-

FOUNDATION,

http://www.biotechhistory.org/

timeline/genentech-ipo/ (last visited Nov. 12, 2014).
10.
See id.
11.
A History of Firsts, supra note 8.
12.
Id.
13.
See id.
14.

Deepinder

Brar,

The History of Insulin, INT'L ISLET TRANSPLANT REGISTRY,

http://www.med.uni-giessen.de/itr/history/inshist.html (last visited Nov. 12, 2014).
15.
See id.
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children suffering from growth hormone deficiency. 16 This time,
instead of licensing its technology to an established pharmaceutical
company, as it had done with insulin, Genentech brought recombinant
hGH to market itself. Genentech's hGH was the first recombinant
pharmaceutical produced and marketed by a biotechnology company."
Significantly, it took nearly a decade and millions of investor dollars.
By bringing hGH to market itself, Genentech set the exemplar for a
generation of conventional biotechnology companies that have pursued
a
business
model
aimed
at becoming
fully integrated
biopharmaceutical firms.
In the ensuing years, Genentech continued to experience
tremendous success and has brought many important biologic drugs to
market, including recombinant tissue-plasminogen activator (t-PA) to
dissolve blood clots in patients suffering from a heart attack,
Pulmozyme (dornase alfa) for treating cystic fibrosis, and the
humanized antibody Herceptin (trastuzumab) for patients with
metastatic breast cancer.' 8 Significantly, all of Genentech's major
products are human drugs.
Genentech remains one of the world's most successful
biotechnology companies, but it is no longer the largest.
That
distinction goes to Amgen, a company founded in Thousand Oaks,
California, in 1980.19 Like Genentech, Amgen initially began with
several millions of dollars in venture capital. 20 The company burned
through that initial investment quickly however, as has been the norm
in conventional biotechnology, and needed to issue stock several times
over the next five years as the company continued to lose money. 21
Amgen eventually turned the corner and broke even financially in
1986, but at the time, its major source of income was research grants
from pharmaceutical companies, not product sales. 22 Finally, in 1989,
Amgen received FDA approval to market its first pharmaceutical
product, recombinant human erythropoietin, sold under the trade
name Epogen. 23 Epogen became an immediate blockbuster success,

16.
A History of Firsts, supra note 8.
17.
Id.
18.
Id.
19.
Robin Walsh, A History of Amgen, PHARMAPHORUM (Oct. 15, 2010),
http://www.pharmaphorum.com/articles/a-history-of-amgen.
20.
Id.
21.
Id.
22.
Id.
23.
See id. Erythropoietin stimulates the production of red blood cells, and the drug was
initially approved for the treatment of anemia associated with kidney dialysis. Id.
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causing Amgen's revenue to increase from $2.8 million in 1989 to
around $140 million in 1990.24
In 1991, Amgen brought its next drug to market, Neupogen-a
recombinant version of G-CSF (granulocyte colony-stimulating factor)
used in treating chemotherapy-induced neutropenia in cancer
patients. 25 By 1992, Amgen's annual sales had reached $1 billion, and
this figure doubled over the next four years. Subsequently approved
Amgen products include Infergen (an anti-hepatitis C medication),
Aranesp (used in the treatment of anaemic patients with chronic renal
failure), and Neulasta (used to treat the same indications as
Neupogen). 26 In 2013, the company reported total revenue of $18.7
billion-$18.2 billion from product sales and Research and
Development expenses of $3.9 billion. 27 Like Genentech, Amgen
continues to remain focused on the development of human drugs,
primarily proteins for use in replacement therapy and engineered
monoclonal antibodies.
Genentech and Amgen established the ideal for conventional
biotechnology and have been emulated by a host of biotechnology
startups, most of which were never able to achieve anything
approaching the success of the few top tier biotechnology companies.
products
of conventional
Although most of the important
biotechnology have been human drugs, from the beginning some
conventional biotechnology companies have pursued the development
of other sorts of products. Probably the most commercially significant
non-pharmaceutical application of conventional biotechnology has
been in the area of agriculture and genetically modified crops.
Monsanto has long been the undisputed global leader in
commercial agricultural biotechnology and to this day, maintains that
dominant position. Monsanto began as a chemical company in 1901
and its first product was the artificial sweetener, saccharin. 28 The
company eventually moved into the production of agricultural
chemicals, particularly herbicides such as glyphosate, sold by
Monsanto under the trade name Roundup. In 1981, the company
formed a molecular biology group and began to focus its resources on
agricultural biotechnology. 2 9 Monsanto scientists participated in the
first successful genetic modification of a plant using recombinant
24.
25.
26.
27.
Amgen.pdf.
28.

Id.
Id.
Id.
AMGEN,
Company

ABOUT AMGEN
History,

1 (2014), http://www.amgen.com/pdfs/misc/FactSheet_
MONSANTO,

monsanto-history.aspx (last visited Jan. 30, 2014).
29.
Id.

http://www.monsanto.com/whoweare/Pages/
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biotechnology in 1982,30 and in 1987, Monsanto conducted the first US
field trials of plants containing biotechnological traits. 31
In 1996, Monsanto brought its first genetically modified crops
These products were developed using the same
to market.3 2
fundamental technologies employed by Amgen and Genentech, i.e.,
introduction of a foreign gene into a cell and expression of the protein
encoded by that gene. 33 The difference is that the commercial
objective of Monsanto scientists was not to purify the protein from the
cell, but rather to use the protein to confer a valuable new trait on the
recombinant organism expressing it. In other words, Monsanto's
product is not the recombinant protein per se, but the entire
recombinant seed and plant that has been engineered to express it.
One of Monsanto's pioneering products was Roundup Ready
soybeans, introduced to the market in 1996.34 These soybeans are
able to thrive in the presence of the herbicide glyphosate, thereby
allowing farmers to spray their field with Monsanto's Roundup-or a
glyphosate product of another company, since Monsanto's patent on
glyphosate has expired-and kill weeds without damaging the crop.
Glyphosate kills non-genetically modified plants by specifically
inhibiting EPSPS (5 -enolpyruvoylshikimate- 3-phosphate synthase), a
metabolic enzyme that only exists in plants and microbes, and as a
consequence, glyphosate is minimally toxic to insects and animals,
including humans. 35 To create Roundup Ready soybeans, Monsanto
scientists identified a strain of bacteria having a mutated form of
EPSPS that naturally resists the effects of glyphosate. 36 Using
recombinant technologies, the scientists introduced the mutant
bacterial EPSPS gene into the soybean, thereby causing the soybean
to express the glyphosate-resistant EPSPS. Monsanto followed up its
30.
Id.; see CHARLES, supra note 7, at 20-21.
31.
Company History, supra note 28; see Wallace E. Huffman, Contributionsof Public
and Private R&D to Biotechnology Innovation, in 10 FRONTIERS OF ECONOMICS AND
GLOBALIZATION: GENETICALLY MODIFIED FOOD AND GLOBAL WELFARE 134 (Colin A. Carter et al.
eds., 2011).

Company History, supra note 28.
32.
33.
Gene expression is the process by which information from a gene is used in the
synthesis of a functional gene product, such as a protein. See Definition of Gene Expression,
MEDICINENET.COM,
http://www.medicinenet.com/script/main/art.asp?articlekey=3564
(last
modified Mar. 19, 2012).
34.

See WENONAH HAUTER, FOODOPOLY: THE BATTLE OVER THE FUTURE OF FOOD AND

.

FARMING IN AMERICA 238 (2012); Company History, supra note 28.
35.
See H.C. Steinrucken & N. Amrhein, The Herbicide Glyphosate Is a Potent Inhibitor
of 5-Enolpyruvyl-Shikimic Acid-3-Phosphate Synthase, 94 BIOCHEMICAL AND BIOPHYSICAL RES.
COMM. 1207, 1207 (1980) ("The broadspectrum herbicide glyphosate (N-[phosphonomethyl]glycine), which causes the accumulation of shikimic acid in plant tissues, inhibits the enzymatic
conversion of shikimic acid to anthranilic acid . .
36.
See CHARLES, supra note 7, at 62-63.
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success in soybeans with a series of other Roundup Ready products,
including cotton, canola, alfalfa, and sugar beets. 37
Another product introduced by Monsanto in 1996 was Bollgard
insect-protected cotton, a genetically engineered plant that is lethal
Monsanto
toward certain insects, particularly the bollworm. 38
cotton
plant a
into
the
by
introducing
the
product
scientists developed
gene encoding a protein that is toxic to certain insects, but not to other
The gene is derived from the bacteria Bacillus
life forms.
thuringiensis (Bt), and plants engineered to express the toxic protein,
such as Bollgard, are commonly referred to as "Bt products."3 9
Organic farmers have long used Bt as a natural biopesticide, and
Bollgard cotton essentially uses the same toxin, but instead of
applying bacteria to the field, the cotton plant produces the
biopesticide itself. 40 Monsanto followed up with a series of other Bt
products targeting other major agricultural pests. 4 1
Interestingly, while Monsanto's herbicide and insect resistant
crops were the first products of agricultural biotechnology to achieve
major commercial success, they were not the first genetically
engineered crops to enter the market. That distinction goes to the
Flavr Savr tomato, created by Calgene, another pioneering
Calgene was reportedly
agricultural biotechnology company. 42
founded in a garage in 1980 as a collaboration between the son of a
prominent Silicon Valley entrepreneur and a biochemistry professor at
the University of California, Davis. 43 In contrast with the other early
commercial applications of biotechnology products described thus far,
instead of introducing a foreign gene into the tomato, Calgene
scientists introduced a recombinant DNA molecule that functioned to
greatly reduce the expression of a gene that occurs naturally in
tomatoes. 44 The targeted gene encodes polygalacturonase (PG), an

http://www.monsanto.com/products/Pages/
MONSANTO,
Seeds,
37.
Agricultural
monsanto-agricultural-seeds.aspx (last visited Feb. 2, 2014).
http://www.monsanto.com/
38.
See History of Bollgard Cotton, MONSANTO,
improvingagriculture/Pages/history-of-bollgard-cotton.aspx (last visited Feb. 2, 2014).
39.
See Global Insect Resistance Management, MONSANTO, http://www.monsanto.com/
products/Pages/insect-resistance-management.aspx (last visited Feb. 2, 2014).
40.
See CHARLES, supra note 7, at 42.
See Global Insect Resistance Management, supra note 39.
41.
42.
See G. Bruening & J.M. Lyons, The Case of the FLAVR SAVR Tomato, 54
CALIFORNIA AGRICULTURE 6, 6 (2000), available at http://ucanr.org/repository/CAO/
landingpage.cfm?article=ca.v054nO4p6&fulltext=yes.
See CHARLES, supra note 7, at 12; Calgene LLC, DAVISWIKI, http://daviswiki.org/
43.
CalgeneLLC (last visited Oct. 13, 2014).
44.
See BELINDA MARTINEAU, FIRST FRUIT: THE CREATION OF THE FLAVR SAVR TOMATO
AND THE BIRTH OF BIOTECH FOOD 35-36 (2001).
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enzyme that was believed to be the key to fruit softening.45 Calgene
researchers introduced a reverse-orientation ("antisense") copy of the
PG gene into the tomato, which caused a reduction of PG expression
by up to 99 percent. 46 The result was a tomato that could be allowed
to ripen on the vine without softening, thereby rendering the tomato
more durable to transport and packaging, while retaining the color
and flavor characteristics of vine ripened tomatoes.
In 1992, the US Department of Agriculture (USDA) determined
that Calgene's PG-antisense tomato lines were not a "plant-pest" risk
and no longer required permits for field-testing or transport. 47 FDA
approved the marketing of the tomato in 1994, finding it to be as safe
as a tomato produced by conventional breeding.4 8 Although the
technology worked, the product was not a commercial success-a fact
that has been largely attributed to Calgene's lack of expertise in the
production and distribution of tomatoes. Basically, the Flavr Savr
tomato could not compete with vine ripened tomatoes that were being
made available on supermarket shelves, not through biotechnology,
but rather by simply taking more care in handling the tomatoes on
their way to market. 49
After the commercial failure of the Flavr Savr tomato,
successful agricultural biotechnology companies like Monsanto have
tended to focus primarily on the development of input traits like
herbicide tolerance and biopesticide expression. Traits of this sort are
referred to as "input traits" because they reduce the inputs required to
grow the product, for example, by permitting more efficient use of
herbicide or less reliance on chemical insecticide.5 0 Essentially, the
companies found they were more likely to convince farmers to pay for
genetic modifications that make farming more efficient than they were
to convince consumers to pay the premium charged for the benefits of
"output traits" like tastier tomatoes. In the future,
however, it is
anticipated that as agricultural biotechnology matures, more
emphasis will be placed on output traits that provide more direct

45.
46.

Id. at 23.
See id. at 35-36.

47.
See ANIMAL & PLANT HEALTH INSPECTION SERv., U.S. DEP'T OF
AGRIC., RESPONSE
TO CALGENE PETITION FOR DETERMINATION OF REGULATORY
STATUS (1992), available at

http://www.aphis.usda.govbrs/aphisdoes2/92-19601p-com.pdf
48.
Press Release, Brad Stone, U.S. Food & Drug Admin., The Flavr Savr
Arrives (May
18, 1994), availableat http://www.accessexcellence.org/RC/AB/IWT/FlavrSavrArrives.php.
49.
See CHARLES, supra note 7, at 144-46; MARTINEAU, supra note 44, at 110-20.
50.
See Lothar Willmitzer, Editorial Overview, PlantBiotechnology: Output Traits-The
Second Generationof Plant Biotechnology ProductsIs Gaining Momentum, 10
CURRENT OPINION
IN BIOTECHNOLOGY 161, 161 (1999), available at http://www.ufv.br/dbv/pgfvg/BVE684/htms/
pdfs-revisaoltrangenicos-transformacaowillmitrev.pdf.
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benefits to consumers, such as improved nutritional properties or
better shelf life. 5 1
Although the main commercial emphasis of conventional
biotechnology has been drugs and agriculture, some conventional
biotechnology companies have chosen to focus on the development of
other sorts of products. For example, since the earliest days the tools
of conventional biotechnology have been enlisted in the production of
improved industrial enzymes.
Industrial enzymes are a type of
protein that is used to catalyze a variety of chemical reactions of
industrial utility.
For example, industrial enzymes are used in
laundry detergent to break the chemical bonds that make some stains
so difficult to remove, and in the production of various products such
as paper, corn syrup, and ethanol. 52 Biotechnology has enabled the
production of large commercial quantities of industrial enzymes by
introducing the gene encoding the industrial enzyme into a
microorganism that can be grown in large fermenters and used as a
sustainable and scalable source of the enzyme. 53
Early in its history, before deciding to focus exclusively on
pharmaceuticals, Genentech devoted some of its resources to applying
biotechnology to the production of recombinant industrial enzymes.
However, in 1982, the company decided to divest that part of its
business as an independent industrial enzyme company called
Genencor-a joint venture with Corning Glass Works. 5 4 Genencor's
earliest products included recombinant proteases for use in laundry
detergents and industrial enzymes used in other processes such as the
production of corn syrup and paper.5 5 Today, Genencor is a subsidiary
of DuPont, and much of its efforts are directed towards the
development of green technologies for the manufacture of products
such as cellulosic ethanol and bio-based plastics.5 6

51.
See id. at 162.
52.
See The Third Wave in Biotechnology: A Primer on Industrial Biotechnology,
BIOTECHNOLOGY INDUSTRY ORG. (Feb. 6, 2012), http://www.bio.org/articles/third-wavebiotechnology.
53.
See id.
54.
See Press Release, Genentech, Corning Glass, Genentech to Form Indus. Enzyme
Co. (Apr. 13, 1982), available at http://www.gene.com/medialpress-releases/4181/1982-0413/corning-glass-genentech-to-form-industri; Oral History by Sally Smith Hughes with Thomas
D. Kiley, Legal Counsel & Vice President, Genentech, 1976-1988
(2001-2002),
http://content.cdlib.org/view?docld=kt9g5Ol5sn;NAAN=13030&doc.view=frames&chunk.id=divo
0141&toc.depth=1&toc.id=div00140&brand=calisphere.
55.
See R. Gupta et al., Bacterial Alkaline Proteases: Molecular Approaches and
IndustrialApplications, 59 APPLIED MICROBIOLOGY & BIOTECHNOLOGY 15, 27 (2002).

56.
See DuPont and the
History of Industrial Biotechnology,
http://biosciences.dupont.com/about-us/history/ (last visited Feb. 2, 2014).
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B. Characteristicsthat Define Conventional Biotechnology Products
and Companies
This Section discusses, in general terms, some of the defining
characteristics of conventional biotechnology companies and their
products, many of which are represented in the above case studies.
These characteristics have played an important role in shaping the
business models and IP imperatives of conventional biotechnology.
Compared to more traditional engineering disciplines, such as
mechanical, electrical, or computer programming, genetic engineering
has historically been seen as a relatively unpredictable and largely
empirical process. This unpredictability is reflected, for example, in
the doctrine of patent enablement, which categorizes chemistry and
biology as relatively unpredictable areas of technology.5 7
One
consequence of the unpredictability has been that the research and
development of products in conventional biotechnology has been a
time-intensive proposition, typically entailing a great deal of
trial-and-error experimentation.
The development of recombinant
human protein drugs by biotechnology pioneers like Amgen and
Genentech, for example, were drawn out processes fraught with
uncertainty.
Moreover, the ultimate success of these particular
products represents the exception rather than the rule-most
conventional biotechnology research and development projects
ultimately fail, and in fact, the majority of conventional biotechnology
startup companies never succeed in bringing a product to market.5 8
Reflecting
the
technical
limitations
of conventional
biotechnology, most conventional biotechnology products have been
based upon the relatively straightforward recombination of naturally
occurring genes and genetic regulatory elements. Typically, only a
single recombinant gene is introduced into any particular product, or
at the most a few genes, such as in a "stacked trait" agricultural
product. For the most part, conventional biotechnology products have
employed cloned copies of naturally occurring genes, rather than
synthetic, human-designed genes, and have not involved the creation
of complex multi-genic constructs.
While these defining characteristics generally hold true, it
would be a mistake to take from this discussion an impression that
conventional biotechnology has ever been an entirely monolithic
enterprise. Since the earliest days of biotechnology, there has been

57.
See, e.g., In re Wands, 858 F.2d 731, 741 (Fed. Cir. 1988).
58.
See Angelo DePalma, Twenty-Five Years of Biotech Trends: Mostly Boom, Some
Busts as the Industry Comes of Age, GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, Aug. 1,
2005, http://www.genengnews.com/gen-articles/twenty-five-years-of-biotech-trends/1005/.
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some movement toward more complex feats of genetic engineering. In
agricultural biotechnology, for example, there has been a trend toward
"stacked" products, in which two or more recombinant genes are
introduced into a single plant. 59 But up until now, the number of
stacked traits has generally been limited to no more than a few per
plant. 60 Significantly, even in the case of a stacked agricultural
product, in most cases, the protein products of these genes function
independently and do not interact synergistically. In a typical case,
for example, the stacked genes might encode multiple insecticidal
proteins targeting distinct insect pests such as corn rootworm, corn
earworm, and corn borer, in addition to an herbicide resistance gene
like Roundup Ready. 61
The observation that conventional biotechnology products tend
to rely on naturally occurring genetic sequences encoding naturally
occurring proteins is likewise subject to some caveats. Conventional
biotechnologists have found it necessary at times to modify the coding
sequence of a naturally occurring gene in order to optimize its
performance in a recombinant context.
For example, one of the
earliest biotechnology drugs was recombinant tissue plasminogen
activator (t-PA), a protein that induces the breakdown of blood clots
and is used to treat heart attack victims. 6 2
In making the
recombinant product, researchers engineered the t-PA gene so that
the recombinant protein it encodes lacks some domains present in the
native protein, resulting in an increased half-life that renders the
protein more effective for use as a human drug. 63
Modifications have also been introduced into the DNA
sequences of recombinant genes in order to facilitate recombination
with other genetic elements, or to permit expression in a non-native
host cell, e.g., expression of a human protein in bacteria. 64 For
example, industrial enzymes have been reengineered by changing one
or a few amino acids to improve a desired functional characteristic
such as thermostability. Still, overall, conventional biotechnology has
tended to rely primarily on the genes and genetic elements provided

59.

See Sorting Out the Facts Behind Stacks, MONSANTO, http://www.monsanto.com/

newsviews/Pages/gene-stacks-facts.aspx (last visited Feb. 2, 2014).
60.

See, e.g., Corn Seeds, MONSANTO,

http://www.monsanto.com/products/Pages/corn-

seeds.aspx (last visited Feb. 2, 2014).
61.
See,
e.g.,
Genuity
VT
Triple
PRO
RIB
Complete,
MONSANTO,
http://www.monsanto.com/products/Pages/genuity-vt-triple-pro-rib-complete-corn.aspx
(last
visited Feb. 2, 2014).
62.
See Genentech, Inc. v. Wellcome Found. Ltd., 29 F.3d 1555, 1558 (Fed. Cir. 1994).
63.
See id.
64.
See CHARLES, supra note 7, at 46 (describing Monsanto's optimization of the Bt gene
for expression in plants).
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by nature, and any modifications to gene sequences that have occurred
have largely fallen into the category of "tweaking" as opposed to whole
scale reengineering of naturally occurring genes.6 5
Conventional biotechnology has also been the subject of much
stricter regulatory oversight than other new technologies, such as
computer and software engineering. This distinction reflects the fact
that the primary products of conventional biotechnology are usually
intended for introduction into the human body, either as food or
medicine.
Regulatory compliance, especially securing marketing
approval for regulated products, dramatically increases the time
and investment capital required to bring a conventional biotechnology
product to market.
The regulatory burden on biotechnology
has, in some instances, been compounded by a widespread
perception-primarily among non-biotechnologists-that the ingestion
of products of biotechnology might result in safety issues, or that the
release of genetically modified organisms into the environment could
pose unique environmental concerns. 66
Biotechnology drugs, for example, are subject to stringent
regulation by FDA. 6 7 Most drugs produced using recombinant DNA
technology are regulated as biologics by FDA under the Public Health
and Safety Act (PHSA), 68 which in some instances tends to impose a
heightened level of scrutiny compared to the already strict review of
new drug applications under the Food, Drug, and Cosmetics Act
(FDCA). 69 This heightened scrutiny has been deemed warranted
because the production of drugs in living organisms is inherently less
predictable than the chemical synthesis used to produce small
molecule drugs, and because protein drugs are much larger and more
chemically complex than small molecule drugs. 70
In the early days of biotechnology, scientists and government
officials assumed that the use of conventional biotechnology to
genetically alter crop plants would require little regulatory oversight,
65.
See Jonathan A. Goler et al., Genetic Design: Rising Above the Sequence, 26 TRENDS
IN BIOTECHNOLOGY 538, 538, 543 (2008); Matthew Herper, Photoshop For DNA, FORBES (June 1,
2009, 6:00 AM), http://www.forbes.com/2005/06/01/cxmh_060 ldna.html.
66.
See PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, GUIDE TO U.S. REGULATION OF
GENETICALLY MODIFIED FOOD AND AGRICULTURAL BIOTECHNOLOGY PRODUCTS 1 (2001).

&

See id. at 3.
67.
68.
See 42 U.S.C. § 262 (2012).
69.
See David E. Adelman & Christopher M. Holman, Misplaced Fears in the Battle
Over Affordable Biotech Drugs, 50 IDEA 565, 567-68 (2010); Joseph A. DiMasi & Henry G.
Grabowski, The Cost of Biopharmaceutical R&D: Is Biotech Different?, 28 MANAGERIAL
DECISION ECON. 469, 472 (2007), available at http://www.manhattan-institute.org/projectfdal
wiley-interscience cost of biopharm.pdf.
70.
See How Do Drugs and Biologics Differ?, BIOTECHNOLOGY INDUSTRY ORG. (Nov. 10,
2010), http://www.bio.org/articles/how-do-drugs-and-biologics-differ.
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since the process is not inherently any more likely than conventional
breeding to result in safety concerns.7 1 Nonetheless, a widespread
backlash against the use of biotechnology in agriculture has resulted
in the creation of a complex system of often overlapping regulatory
requirements specifically applicable to the products of biotechnology.7 2
A recombinant agricultural product might require regulatory approval
by FDA as a food (if the product is used as a food for humans or
animals), or by the Environmental Protection Agency (EPA) as a
pesticide (if it has been engineered to express a pesticide), or by the
USDA if it poses a potential threat as an agricultural pest (if, for
example, it could become an invasive weed). 73 A product might fall
under all three regulatory regimes, such as a soybean with stacked Bt
and herbicide resistance traits-the soybean is food, the Bt is a
pesticide, and the herbicide resistance gene might potentially pose a
threat if it were to find its way into a weed.
Bringing a conventional biotechnology product to market has
traditionally required a huge investment of time and capital. The
unpredictability associated with living biological systems, and the
largely empirical nature of conventional biotechnology, has tended to
slow the pace of research and development, and stringent regulatory
requirements create a further delay to market entry. In the case of a
biologic drug, for example, the pathway to commercialization involves
a prolonged research and development process, coupled with extensive
testing for safety and efficacy that begins in the laboratory,
progressing from in vitro systems to animals, and ultimately
concluding with expensive human clinical trials. At any point in the
process, there is a risk that the putative product will fail for any of a
variety of reasons. The commercialization of conventional agricultural
biotechnology products is also a lengthy and unpredictable process,
beginning with the development of the recombinant trait in the
laboratory, followed by the years of conventional breeding necessary to
introduce the trait into commercially viable seeds, and the cost of
obtaining regulatory clearance. 74
The strict regulatory approval of genetically modified
agricultural products can be particularly burdensome for smaller

71.

See CHARLES, supranote 7, at 28.

72.

See id. at 28-30; PEW INITIATIVE ON FOOD & BIOTECHNOLOGY, supra note 66, at ii-

I1.

73.
See PRESIDENTIAL COMM'N FOR THE STUDY OF BIOETHICAL ISSUES, NEW DIRECTIONS:
THE ETHICS OF SYNTHETIC BIOLOGY AND EMERGING TECHNOLOGIES 81, 101 (2010), available at

.

http://bioethics.gov/sites/default/files/PCSBI-Synthetic-Biology-Report-12.16.10-0.pdf.
74.
See Patrick Ambrosio, DuPont Pioneer Seed Prepares for Climate Change,
Frustrated with Farm Bill Progress, 37 CHEMICAL REG. REP. 314, 314 (2013) ("It takes . .
between 10 and 20 years to develop and get to market a new biotech trait .... ).
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companies that may find it difficult to afford the high cost of
compliance. In fact, it has been reported that in the 1980s FDA's
designated spokesman for biotechnology came to believe that
"Monsanto's campaign for regulations on biotechnology was really
intended to squeeze out smaller, more nimble but less well funded
competitors. Monsanto could easily afford to spend millions of dollars
to test a new product; small startups like Calgene could not."

5

In any event, regardless of a company's size, the substantial
cost, time, and risk associated with bringing conventional
biotechnology products to market have rendered the ability to attract
investment capital a critical factor in the success of most conventional
biotechnology companies.
Venture capitalists in particular have
played an important role, and have been directly involved in
launching biotechnology companies like Amgen and Genentech.
Indeed, it is not uncommon for a conventional biotechnology company
to sell stock on the public equity market prior to launching a
product.7 6 Conventional biotechnology companies only survive if they
can convince investors of a reasonable likelihood of substantial
returns at some distant point in the future.
In this regard, Monsanto is a bit atypical among the pioneers of
conventional biotechnology, in that it was already a well-established
company prior to moving into biotechnology. Although Monsanto's
corporate survival was not directly dependent upon outside investors,
the company had to take on a "crushing burden of debt" to fund its
biotechnology ambitions, and to do this they had to "persuade Wall
Street .

. . that the potential rewards of biotechnology were worth

almost any short-term burden."77 It has been reported that some
Monsanto executives questioned the wisdom of investing in
biotechnology based on their perception that the likely return on
investment would not justify the cost and uncertainty associated with
the company's trailblazing biotechnology research and development.78
Monsanto has pursued a blockbuster mentality focused on the
discovery of "blockbuster genes, gifts from nature that the scientists
might be able to claim as their own, transfer into plants, and sell for
hundreds of millions, if not billions, of dollars."7 9 The company
75.
76.

CHARLES, supra note 7, at 28.
See, e.g., A History of Firsts, supra note 8; Genentech IPO, supra note 9; see also TOM

ABATE, THE BIOTECH INVESTOR: How TO PROFIT FROM THE COMING BOOM IN BIOTECHNOLOGY

192 (2003) ("Many [biotech] companies go public long before they have products to sell.").
77.

CHARLES, supra note 7, at 202.

78.
See id. at 26, 38 (noting many Monsanto executives considered biotechnology "a
research project with highly questionable commercial prospects" and the company's
biotechnology program "a foolish, harebrained boondoggle").
79.
Id. at 40.
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envisioned Roundup-resistant crops as "blockbuster products" that
would add hundreds of millions of dollars, if not billions, to the
company's profits.8 0 Indeed, Monsanto has been described as "a home
run company. . . . If it's not a billion-dollar product, they don't want

to hear about it."81
Conventional biotechnology companies have needed to
persuade investors to accept a high degree of risk. To this end, they
have tended to focus on products seen as having the potential for
extreme profitability, i.e., blockbuster products. Revolutionary and
life-saving drugs of the type marketed by Amgen and Genentech are
the epitome of blockbuster products. 8 2
Although agriculture is generally not considered as lucrative as
the pharmaceutical business, agricultural biotechnology companies
have in their own way also tended to focus on blockbuster products.
The management and scientists at Calgene, for example, firmly
believed that their Flavr Savr tomato would come to dominate the
billion-dollar tomato market, generating hundreds of millions of
dollars in profits. 83 Although the tomato failed to live up to the
company's expectations, when the decision was made to invest in the
product, Calgene thought it was on the road to becoming the next
Genentech or Apple.
Similarly, Monsanto set its sights on developing products for
the most commercially important US row crops, including cotton, corn,
and soybeans. These are huge markets, and Monsanto saw that if it
could dominate them, it could generate revenues in the hundreds of
millions of dollars, the sort of return necessary to justify the
company's large investment in conventional biotechnology. Critics of
agricultural biotechnology sometimes complain that the early products
of companies like Monsanto focused too much on input traits that
improve the bottom line of farmers, rather than output traits that
would improve the quality of the product experienced by the
consumer. 84 But Monsanto apparently concluded that farmers would
be more likely to pay for the value of input traits than consumers
would be to pay for output traits-a view that would be entirely
consistent with the failure of the Flavr Savr tomato-and instead
80.
81.
82.
conventional

See id. at 73.
Id. at 157 (internal quotation marks omitted).
An increasing number of the world's most profitable drugs are the products of
biotechnology. See Krishan Maggon, R&D Paradigm Shift and Billion-Dollar

Biologics, in HANDBOOK OF PHARMACEUTICAL BIOTECHNOLOGY 177, 179 (Shayne Cox Gad ed.,

2007).
83.

CHARLES, supra note 7, at 131-32.

84.
See TADLOCK COWAN,
CONG. RESEARCH SERV.,
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focused its energy on the products it viewed as most likely to achieve
blockbuster status.8 5
Overall, the road to profitability has been long and uncertain in
conventional biotechnology.
Many biotechnology companies have
spent millions of dollars and toiled many years only to ultimately shut
down without ever producing a commercial product. During a 2005
interview, one biotechnology executive posited that "only one in ten
biotech companies is profitable." 86 Investors are well aware of the
high risk and high cost of developing biotechnology products and will
normally only be willing to invest in biotechnology if they believe that
success has the potential to lead to a very large payoff. The demands
of these investors have in turn led most conventional biotechnology
companies to focus largely on the blockbuster model.8 7 This model
appeals to venture capitalists, most of whom are more interested in
buying a chance at a blockbuster product than investing in a company
pursuing the development of less risky products with less potential for
upside profitability.8 8
Although most conventional biotechnology products are
developed in the private sector, universities and other academic
research institutions also play an important role in conventional
biotechnology.
While generally not directly involved in product
development, these institutions often patent and license biotechnology
inventions to for-profit companies for commercialization, a practice
often somewhat euphemistically referred to as "technology transfer."
Universities are normally thought of as non-commercial entities, but
they still tend to rely heavily on the biotechnology blockbuster model.
Universities are often very enthusiastic about commercializing their
technology, but research suggests that most universities are lucky to
break even in their technology transfer endeavors.8 9 The relatively
few examples of universities profiting from technology transfer are, for

85.
See Diana L. Moss, Transgenic Seed: The High Technology Test of Antitrust?, 2 CPI
ANTITRUST J. 1, 2 (2010).
86.
DePalma, supra note 58.
87.
See John Carroll, Onyx Wraps NDA for Blockbuster Cancer Drug Hopeful
Carfilzomib, FIERCEBIOTECH (Sept. 28, 2011), http://www.fiercebiotech.com/story/onyx-wrapsnda-blockbuster-cancer-drug-hopeful-carfilzomib/20 11-09-28; Ryan McBride, MorphoSys Zeroes
in on Partner for Blockbuster Hopeful Against Arthritis, FIERCEBIOTECH (Sept. 21, 2012),
http://www.fiercebiotech.com/story/morphosys-zeroes-partner-blockbuster-hopeful-againstarthritis/2012-09-21; Luke Timmerman, Where Are Tomorrow's Blockbuster Biotech Drugs
Coming from? You Might Be Surprised, XCONOMY (Mar. 14, 2011), http://www.xconomy.com/
national/2011/03/14/where-are-tomorrows-blockbuster-biotech-drugs-coming-from-you-might-besurprised/.
88.
See DePalma, supranote 58.
89.
See Jay P. Kesan, TransferringInnovation, 77 FORDHAM L. REV. 2169, 2180 (2009).
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the most part, based on the success of a handful of blockbuster
products.9 0
III. THE ROLE OF IP IN CONVENTIONAL BIOTECHNOLOGY

The prevailing business model of conventional biotechnology
has long been premised upon the availability of effective IP protection.
Without the prospect of some period of market exclusivity, and the
consequent opportunity for high profit margins, investors would be
reluctant to invest in the expensive, risky, and prolonged process of
conventional biotechnology product development.
Conventional
biotechnology companies have succeeded in convincing investors that
IP-particularly, although not exclusively, in the form of patents-will
be available to protect the fruits of their investment.9 1
These
companies fear that even a perception of less than robust IP protection
for innovations in biotechnology could chill investment, and they have
vigorously advocated for a strong patent system. 92 This Part discusses
the role of IP in conventional biotechnology.
A. Patents and Conventional Biotechnology
Although patents are not the only form of IP that plays a role
in conventional biotechnology, from its earliest days investors and
companies have viewed the development of a strong patent portfolio as
a critical element of success. Patents have been called "the bedrock on
which the biotechnology industry is built." 9 3
According to Kate
Murashige, a lawyer who worked for Genentech in the 1980s, "The
management of Genentech, when I worked there, was convinced that,
were it not for patents, they could not survive as a company. It was
always considered an essential part of the business plan." 9 4
A similar sentiment seems to have existed at Monsanto.
According to Howard Schneiderman, a molecular biologist who left
academia in the early 1980s to become Monsanto's chief scientist, the
company executives soon taught him that brilliant discoveries are only
useful to the company if they lead to a "proprietary position." 95 They
stressed that a good idea would only be a profitable idea if it could be
protected, and patents were seen as the primary legal mechanism for
90.
See id. at 2180-81.
91.
See Christopher M. Holman, Biotechnology's Prescriptionfor Patent Reform, 5 J.
MARSHALL REV. INTELL. PROP. L. 318, 327-28 (2006).
92.
See id. at 330.
93.
CHARLES, supra note 7, at 19.
94.
Id. at 10-11 (internal quotation marks omitted).
Id. at 20.
95.
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protecting ideas. Similarly, the head of Mycogen, another pioneering
agricultural biotechnology company, reportedly "saw the early
competition in biotechnology as a kind of Oklahoma Land Run, a race
for property rights."9 6
Monsanto and Genentech sought patent protection not only for
the products they hoped to commercialize, but also on more
fundamental and generally applicable tools of biotechnology developed
by company scientists.9 7 Patents are generally seen as a primary
mechanism by which conventional biotechnology companies are able to
capture the value created by their research and development
activities. Even if a company never brings a product to market, its
patents and pending patent applications have their own intrinsic
value, and in many cases end up being a biotechnology company's
most important assets.9 8
In fact, it is not uncommon for a
biotechnology company to be acquired solely for the purpose of
obtaining ownership of the company's patent portfolio. 99
Not surprisingly, during the recent prolonged debate in
Congress over patent reform, representatives of the biotechnology
industry were among the staunchest advocates for maintenance of a
strong patent system.1 00
Biotechnology companies and academic
institutions have long argued that investment in biotechnology would
be seriously harmed if investors perceive even the possibility that
effective patent protection will not be available for the results of their
investment.oi
Any discussion of the role of patents in biotechnology would be
remiss if it failed to note the significance of the US Supreme Court's
landmark 1980 decision in Diamond v. Chakrabarty, which declared
genetically modified organisms eligible for patent protection.102
Chakrabarty came at a time when significant doubt existed as to the
availability of effective patent protection for innovations in
biotechnology, and this uncertainty had threatened the viability of the
nascent industry. 103 The Court's decision to grant certiorari and
96.
Id. at 48.
97.
See Holman, supra note 91, at 329-30, 333, 335.
98.
See BIOTECHNOLOGY INDUS. ORG., supra note 6, at 77.
99.
See CHARLES, supra note 7, at 87 (describing one biotechnology company's
acquisition of another company solely for the ownership of its patents).
100.
See Press Release, Biotechnology Indus. Org., BIO Supports Patent Reform Act of
2011 (Jan. 28, 2011), available at http://www.bio.org/media/press-release/bio-supports-patentreform-act-2011.
101.
Holman, supra note 91, at 327-28.
102.
See Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980).
103.

See ERNST & YOUNG, BEYOND BORDERS: GLOBAL BIOTECHNOLOGY REPORT 2006, at

12
(2006),
available at
https://www2.eycom.ch/publications/itemsfbiotech-report/2006/
2006_EYGlobalBiotech.Report.pdf.
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decide the case in favor of patent protection for biotechnological
inventions was, in all likelihood, influenced by the Justices'
recognition of the powerful potential for biotechnology to improve the
human condition.
Although
Chakrabarty
specifically
addressed
the
patent-eligibility of genetically modified organisms, it was widely
interpreted as more broadly signaling the availability of patent
protection for engineered DNA and other innovations likely to arise
out of conventional biotechnology. 1 0 4 After Chakrabarty, the US
Patent and Trademark Office (PTO) reportedly issued a large number
of biotechnology patents that had previously been held up due to
uncertainty with respect to the patent-eligibility of the claimed subject
matter."o'

The Court of Appeals for the Federal Circuit followed up on
Chakrabartywith a number of important decisions that promoted the
availability of effective patent protection for biotechnological
inventions. For example, in 1988, In re Wands reversed a decision by
the PTO Board of Patent Appeals and Interferences (BPAI) affirming
an examiner's rejection of a patent claim reciting a broad genus of
functionally defined antibodies for failure to satisfy the enablement
requirement.106 The rejection was based on the patent examiner's
assertion that it would require too much experimentation to produce
antibodies falling within the scope of the claim.' 0 7 In reversing the
rejection, the Federal Circuit faulted the BPAI for applying the
enablement requirement too strictly, and held that the claim satisfies
the enablement requirement so long as those working in the field
would not consider the amount of experimentation required to identify
the claimed antibodies to be "undue."10 8 In re Wands, and other
enablement decisions by the Federal Circuit relating to biotechnology
inventions, established a relatively permissive enablement standard
that generally allows for broad patent protection for biotechnology
inventions. 109

104.

See KEVIN F. HOWE, THE RIGHT TO OBTAIN PATENT PROTECTION ON LIVING

MATERIAL: THE CAUSES AND CONSEQUENCES OF THE UNITED STATES SUPREME COURT DECISION
IN THE CASE OF DIAMOND V. CHAKRABARTY 6-7 (2007).

105.
See id. at 7.
106.
See In re Wands, 858 F.2d 731, 733 (Fed. Cir. 1988).
107.
See id. at 735.
See id. at 739.
108.
109.
See, e.g., Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1384 (Fed.
Cir. 1986). But see Dan L. Burk & Mark A. Lemley, Policy Levers in Patent Law, 89 VA. L. REV.
1575, 1676-83 (2003).
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In 1993 and 1995, the Federal Circuit issued decisions in In re
Belli"0 and In re Deuell" that were widely interpreted as having
effectively lowered the obviousness bar with respect to claims directed
towards novel DNA molecules. 112 Prior to these decisions, the PTO
and BPAI applied a stricter standard, which might have severely
limited the availability of effective patent protection for the
fundamental building blocks of early biotechnology innovation, i.e.,
newly isolated genes. 113 Bell and Deuel established what many
considered to be a uniquely low obviousness bar for biotechnology
inventions, particularly those involving novel DNA sequences.11 4 In
any event, the low bar facilitated the ability of biotechnology
companies to obtain patents on commercially significant genes,
thereby encouraging investment in the development of drugs and
other biotechnology products based on recombinant genes and their
encoded proteins.
While these judicial decisions from the 1980s and early 1990s
helped establish a very favorable environment for patenting in
biotechnology, in recent years the courts have begun to pull back
somewhat from this permissive approach, resulting in some
contraction in the effective availability of patent protection for
biotechnology. For example, the Federal Circuit's 1997 decision, in
Regents of the University of California v. Eli Lilly seemed to take away
much of the benefit of the permissive enablement standard previously
established by Wands."' Eli Lilly essentially created a new form of
the written description requirement-sometimes referred to as the
"Lilly written description requirement"-that on its face appeared to
substantially heighten the disclosure requirement with respect to
biotechnology inventions, particularly those based on the discovery of
novel DNA sequences. 16
Many commentators, including former Chief Judge of the
Federal Circuit Randall Rader, initially viewed the Lilly written
description requirement as a devastating development for
biotechnology, potentially foreclosing the possibility of effective patent
protection for many DNA-based inventions and perhaps biotechnology
110.
In re Bell, 991 F.2d 781 (Fed. Cir. 1993).
111.
In re Deuel, 51 F.3d 1552 (Fed. Cir. 1995).
112.
See Dan L. Burk & Mark A. Lemley, Is Patent Law Technology-Specific?, 17
BERKELEY TECH. L.J. 1155, 1178-82 (2002).
See id.
113.
114.
See id.
115.
See Regents of Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1568-69 (Fed. Cir.
1997); Janice M. Mueller, The Evolving Application of the Written Description Requirement to
BiotechnologicalInventions, 13 BERKELEY TECH. L.J. 615, 615 (1998).
116.
Mueller, supra note 115, at 615.
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inventions in general.1 17
However, in subsequent decisions, most
particularly the Federal Circuit's decision in Enzo Biochem, Inc. v.
Gen-Probe, Inc.,11 s the Federal Circuit retreated from the apparently
strict standard set forth in Eli Lilly, adopting a more moderate,
although ill-defined, interpretation of the doctrine that has proven
difficult-some would say impossible-to distinguish from the
traditional requirement of enablement. 119
Although the Federal
Circuit has never clearly explained the purpose of the Lilly written
description requirement or how it differs from the enablement
requirement, in 2010, a divided en banc Federal Circuit decided Ariad
Pharmaceuticals,Inc. v. Eli Lilly & Co. in a manner that affirmed the
continuing vitality of the doctrine. 120 Biotechnology companies have,
for the most part, learned to live with the Lilly written description
requirement, and in fact some major biopharmaceutical companies,
like Amgen and GlaxoSmithKline, filed amicus briefs in Ariad
supporting the doctrine. 121
In re Kubin, decided by the Federal Circuit in 2009, withdrew
slightly from the arguably over-permissive obviousness standard for
DNA inventions set forth in Bell and Deuel. 122 Kubin essentially held
that the proper standard for assessing the obviousness of
biotechnology inventions is no different than that which is to be
applied to any other invention. 123
This holding was significant,
because prior to Kubin, many commentators had interpreted Bell and
Deuel as establishing an exceptionally low bar for nonobviousness
uniquely applicable to biotechnology inventions. 124
The Supreme Court's 2012 decision in Mayo Collaborative
Services v. Prometheus Laboratories, Inc. pulled back somewhat from
the broad view of patent-eligible subject matter in biotechnology
articulated by the Court in Chakrabarty.125 In fact, a literal reading of

117.
See Christopher M. Holman, Is Lilly Written Description a Paper Tiger?: A
Comprehensive Assessment of the Impact of Eli Lilly and Its Progeny in the Courts and PTO, 17
ALB. L.J. SCI. & TECH. 1, 4, 17-18 (2007).
Enzo Biochem, Inc. v. Gen-Probe, Inc., 323 F.3d 956 (Fed. Cir. 2002).
118.
119.
See Holman, supra note 117, at 23-25, 80.
120.
See Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1349-51 (Fed. Cir. 2010).
121.
See Kevin E. Noonan, Amicus Briefs in Ariad v. Lilly: Briefs by Companies, PATENT
DOCS (Dec. 6, 2009), http://www.patentdocs.org/2009/12/amicus-briefs-in-ariad-v-eli-lilly-briefsby-companies.html; Donald Zuhn, Amicus Briefs in Ariad v. Lilly: GlaxoSmithKline, PATENT
DOCS
(Nov.
24,
2009),
http://www.patentdocs.org/2009/1 1/amicus-briefs-in-ariad-v-lillyglaxosmithkline.html.
122.
See In re Kubin, 561 F.3d 1351, 1358-59 (Fed. Cir. 2009).
123.
See id. at 1361.
124.
See Burk & Lemley, supra note 112, at 1194-95.
125.
See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1296-98
(2012).
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Mayo might lead one to conclude that the Supreme Court has
significantly narrowed the availability of patent protection for
biotechnology. 126 However, Justice Breyer wrote the decision in vague,
malleable terms that seem amenable to an interpretation that would
leave intact the patent-eligibility of most biotechnology inventions. 127
In Mayo, the Court indicated that it did not intend to foreclose
adequate patent protection for drugs, which further supports an
inference that Mayo should not be interpreted as dramatically altering
the patent-eligibility landscape in biotechnology. 12 8
For decades, the patent community has assumed that claims to
isolated DNA molecules are patent-eligible, even if the sequence of the
DNA molecule corresponds to a naturally occurring genetic sequence.
Based on this understanding, the PTO has issued thousands of
patents containing isolated DNA claims of this sort, and the Federal
Circuit has issued decisions upholding their validity.1 29 However,
until quite recently, the courts have never specifically addressed the
patent-eligibility of these claims, which is perhaps surprising in view
of the large number of isolated DNA claims that have been issued and
their apparent importance to biotechnology firms. When the courts
did finally take up the question, the issue quickly made its way up to
the Supreme Court. In its 2013 decision of Association for Molecular
Pathology v. Myriad Genetics, Inc., the Court ultimately ruled that
isolated fragments of naturally occurring genomic DNA are in fact
ineligible for patent protection. 130 Myriad has been met with more
than a little consternation by many in biotechnology since it casts into
doubt the validity of innumerable patent claims issued during a time
when the patent office believed such molecules to be eligible for patent
protection. 131
At this point, the full impact of Myriad on the patenting of
DNA and other biotechnology inventions remains undecided and will
depend largely upon how the lower courts and the PTO interpret the
decision. While it seems reasonably apparent that Myriad precludes
the patenting of native DNA molecules and other biomolecules that
have simply been purified from a natural source, it is unclear the
extent to which synthetic molecules sharing a common structure with
126.
See Christopher M. Holman, Preliminary Thoughts on Mayo v. Prometheus: The
Implicationsfor Biotechnology, 31 BIOTECHNOLOGY L. REP. 111, 112 (2012).
See id. at 113.
127.
128.
See Mayo, 132 S. Ct. at 1302.
129.
See, e.g., Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200 (Fed. Cir. 1991).
130.
See Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2111
(2013).
131.
See Emma Barraclough, What Myriad Means for Biotech, WIPO MAGAZINE, Aug.
2013, at 21.
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The Court
a naturally occurring molecule remain patent-eligible.
explicitly held that cDNA molecules with sequences corresponding
exactly to naturally occurring mRNA are patent-eligible, based at
least in part on the fact that cDNA molecules do not occur in nature,
but instead are the product of laboratory synthesis. This is the case
even though cDNA is highly similar in chemical structure to the
corresponding native, mRNA, and embodies the same genetic
information. Following this logic, it seems that a strong argument
could be made that many, if not all, of the synthetic DNA molecules
resulting from synthetic biology will be found sufficiently distinctive
from any naturally occurring DNA to maintain eligibility for patent
protection.
B. Patents Generally Satisfy the IP Imperatives of Conventional
Biotechnology
Although recent judicial decisions appear to have somewhat
limited the availability of effective patent protection for biotechnology
inventions, at least relative to the expansive interpretations of the law
set forth in the decisions like Chakrabarty, Wands, and Deuel, the
consensus among biotechnology patent attorneys I have spoken to
appears to be that adequate patent protection remains available to
most conventional biotechnology innovators, particularly those
engaged in biopharmaceutical research. For example, Mayo appears
more likely to adversely impact the patenting of methods used early in
the drug discovery process-sometimes referred to as research tool
patents or upstream patents-than downstream methods of
manufacturing or using the final product. The reason is that these
upstream patents are probably more likely to be found patent
ineligible for "embodying" or "preempting" a natural biological
principle-two of the key indicators of patent ineligibility identified in
Mayo and other relevant Supreme Court precedent. 132 In Mayo, the
Court noted that the decision is not intended to limit the availability
of patent protection for drugs. 133 In any event, even in the absence of
patent protection, biotechnology companies will in many instances
still be able to protect methods developed and used internally in drug
134
discovery and drug manufacturing as trade secrets.
In fact, tightening up the standards of patentability with
respect to fundamental biological discoveries and research tools could
actually be viewed as a positive development for many conventional

132.
133.
134.

Mayo, 132 S. Ct. at 1294.
See id. at 1302.
See infra Part III.C.
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biotechnology companies, particularly those engaged in developing
While established biopharmaceutical
and marketing drugs.
companies that use biotechnology in the drug development process,
such as Eli Lilly and Amgen, actively advocate for strong protection
for their drug products, they also tend to favor policies that would
discourage the patenting of upstream research toolS. 13 5
For example, Eli Lilly recently filed an amicus brief in Myriad
urging the Federal Circuit to adopt a much stricter standard for
patent-eligibility, which would result in the invalidation of a Myriad
patent claim directed towards methods of using the BRCA gene in a
cell-based assay designed to identify pharmaceutically active
compounds.1 36
Similarly,
several years
ago,
some major
biopharmaceutical companies filed amicus briefs in In re Fisher urging
the Federal Circuit to institute a heightened utility bar for claims
directed to isolated DNA sequences.1 37 These amicus filings illustrate
that while conventional biotechnology companies generally view the
availability of adequate patent protection for commercial products as
critical to their viability, many would favor restrictions on the
availability of patent protection for technologies used in upstream
research and product development.
To a large extent, the recent tightening of the requirements of
patentability poses less of a problem for conventional biotechnology
than the high level of unpredictability and uncertainty currently
plaguing US patent law.1 38 Biotechnology executives will tell you that
they can adapt to heightened patentability standards and more
limited patent protection, but that it is difficult to convince investors
to invest in expensive and risky research and product development
when the rules of the game are unclear and constantly shifting.1 39
Unfortunately, the uncertainty with respect to patent validity and
claim scope is so pronounced that some commentators have gone so far
as to characterize patents as nothing more than "probabilistic
property rights."1 40 The Federal Trade Commission (FTC) has cited
this literature to argue that drug patents provide nothing more than a
135.
See, e.g., Brief for Eli Lilly & Co. as Amicus Curiae Supporting Neither Party, Assoc.
for Molecular Pathology v. U.S. Patent & Trademark Office, 689 F.3d 1303 (Fed. Cir. 2012) (No.
10-1406).
136.
See id.
137.
See Brief for Eli Lilly & Co. et al. as Amicus Curiae Supporting USPTO, In re
Fisher, 421 F.3d 1365 (Fed. Cir. 2005) (No. 04-1465), 2004 WL 4996616; Brief for Genentech, Inc.
as Amicus Curiae Supporting USPTO, In re Fisher, 421 F.3d 1365 (No. 04-1465).
138.
See Christopher M. Holman, Unpredictability in Patent Law and Its Effect on
PharmaceuticalInnovation, 76 MO. L. REV. 645, 646 (2011).
See id. at 648.
139.
140.
Mark A. Lemley & Carl Shapiro, ProbabilisticPatents, 19 J. EcoN. PERSP. 75 (2005)
(quotation in abstract).
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In biotechnology, as in other areas of
potential right to exclude. 14'
technology, it is not uncommon for an innovator to have its patents
invalidated when attempting to enforce them, or for a court to
interpret their claims so narrowly that they do not cover their
competitor's product. 142
In part, the uncertainty plaguing biotechnology and
pharmaceutical patent law reflects the unpredictability of the
underlying science. But it also reflects substantial uncertainty in the
law itself, because many important questions regarding the scope and
validity of biotechnology patents remain unresolved by Congress and
the courts. For example, claims reciting isolated DNA molecules were
issued in thousands of patents during a thirty-year period, but the
patent-eligibility of these claims was not addressed by the courts until
quite recently in Myriad.
Recognizing the importance of clarity and predictability in
patent law, the Federal Circuit has on numerous occasions attempted
to define objective and relatively clear criteria for establishing
patentability and infringement. 14 3 Unfortunately, the Supreme Court
has repeatedly overruled these efforts in decisions such as Bilski v.
Kappos, Mayo Collaborative Services v. Prometheus Laboratories,Inc.,
KSR International Co. v. Teleflex, Inc., Quanta Computer, Inc. v. LG
Electronics, Inc., and Festo Corp. v. Shoketsu Kinzoku Kogyo
Kabushiki Co.1 4 4 Mayo in particular has recast the doctrine of
patent-eligibility in a manner that undermines the presumption of
validity for a host of biotechnology patents. 145
At the same time, the Federal Circuit has itself contributed to
the unpredictability of patent law, particularly as it is applied to
biotechnology. As noted by former Chief Judge Rader of the Federal
Circuit, the Lilly written description requirement is essentially a
biotechnology-centric doctrinal wildcard for invalidating unworthy

141.
See Christopher M. Holman, Do Reverse Payment Settlements Violate the Antitrust
Laws?, 23 SANTA CLARA COMPUTER & HIGH TECH. L.J. 489, 515 (2007).
142.
See Christopher M. Holman, Learning from Litigation: What Can Lawsuits Teach
Us About the Role of Human Gene Patents in Research and Innovation?, 18 KAN. J.L. & PUB.
POL'Y 215, 232 (2009) [hereinafter Holman, Learning from Litigation]; see also Christopher M.
Holman, The Impact of Human Gene Patents on Innovation and Access: A Survey of Human Gene
Patent Litigation, 76 UMKC L. REV. 295, 349, 355 (2007) [hereinafter Holman, Impact of Human
Gene Patents] (providing examples where innovators had their patents invalidated).
143.
See Holman, supra note 138, at 662-71.
144.
Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 (2012); Bilski
v. Kappos, 561 U.S. 593 (2010); Quanta Computer, Inc. v. LG Elecs., Inc., 553 U.S. 617 (2008);
KSR Int'l Co. v. Teleflex, Inc., 550 U.S. 398 (2007); Festo Corp. v. Shoketsu Kinzoku Kogyo
Kabushiki Co., 535 U.S. 722 (2002).
145.
See Christopher M. Holman, Mayo, Myriad, and the Future of Innovation in
Molecular Diagnosticsand PersonalizedMedicine, 15 N.C. J.L. & TECH. 639, 667 (2014).
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patent claims. 146 It has been over fifteen years since the court decided
Eli Lilly, yet still, the Federal Circuit has failed to provide any
coherent explanation as to the criteria to be used in assessing
compliance with the doctrine. 147 The Federal Circuit has also recently
expanded the judge-made doctrine of obviousness-type double
patenting in a manner that creates unpredictability with respect to
the validity of some biotechnology patents.1 48
For the most part, conventional biotechnology companies have
been able to manage the uncertainty and unpredictability of patent
law. It has of course forced biotechnology companies to expend more
time and money on patents than they might otherwise have done
under a more predictable patent regime, but in a business
environment dominated by a relatively small number of highly
profitable products, biotechnology companies have been willing to
make the necessary investment to build and maintain their patent
portfolios in a manner that, to a large extent, addresses and
ameliorates the unpredictability.149
For example, uncertainty about the validity and scope of a
particular type of patent claim can be addressed by filing multiple
patent applications and prosecuting a large number of patent claims
directed towards various aspects of a biotechnology product. Amgen's
portfolio of patents relating to its recombinant erythropoietin products
50
aptly illustrates this approach.o
Over the course of many years,
Amgen obtained multiple patents directed towards various methods
and reagents used in the production of recombinant erythropoietin,
with claims directed not only to the DNA sequence encoding
erythropoietin, i.e., the erythropoietin gene, but also to various
recombinant vectors and cells used in the expression of the gene.' 51
Amgen also obtained a number of patents with claims directed
towards various aspects of the therapeutic use of recombinant
erythropoietin, including pharmaceutical compositions comprising
erythropoietin and methods of using erythropoietin as a drug.152

146.
Brief for Christopher M. Holman as Amicus Curiae Supporting Neither Party, Ariad
Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (No. 08-1248), 2009 WL 3711551.
147.
See id.
148.
Brief for Biotechnology Industry Organization as Amicus Curiae Supporting Eli
Lilly & Co.'s Combined Petition for Panel Rehearing and Rehearing En Banc, Sun Pharm. Indus.
v. Eli Lilly & Co., 625 F.3d 719 (Fed. Cir. 2010) (No. 10-1105), available at http://www.bio.org/
sites/default/files/BIO-amicus briefSun vLilly-0.pdf.
149.
See Holman, supra note 138, at 675.
150.
See Holman, Impact of Human Gene Patents, supra note 142, at 329-30.
See id.
151.
152.
See id.
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Amgen's investment in building a robust patent portfolio
around erythropoietin has paid off, and the company has successfully
asserted its erythropoietin patents against competitors on a number of
occasions. 5 3 In the course of these high-stakes patent litigations,
quite a few of Amgen's asserted patent claims have been found to be
invalid, while others have been found not to have been infringed-not
a surprising outcome in view of the uncertainty of biotechnology
patent law.1 54 Nonetheless, because of its large number of patents
with claims of various scope directed towards different aspects of
making and using erythropoietin as a drug, Amgen has prevailed with
respect to at least some of their claims, and a finding of infringement
with respect to even a single valid claim can be sufficient to enjoin a
competitor from entering the market.15 5 Note that because a company
like Amgen is focused on the development of a relatively small number
of blockbuster products, it can afford to focus a great deal of its legal
resources on securing a thicket of overlapping patents around its
products, hopefully creating a redundancy that can ameliorate against
the uncertainty inherent to patent law, particularly as it is applied to
conventional biotechnology.
Unpredictability with respect to patent scope and validity not
only makes it difficult for a company to predict whether its patents
will effectively protect its products, but it also makes it difficult to
assess whether a product in development might infringe someone
else's patent.1 56 However, the business model pursued by most
conventional biotechnology companies tends to attenuate such
"freedom to operate" concerns. For one thing, if the company is only
pursuing the commercialization of a relatively small number of
blockbuster products, the number of freedom to operate issues it will
face will be less than would be the case for a company seeking to
Not only that, the
commercialize a larger number of products.
products of conventional biotechnology have tended to involve the
recombination of a relatively small number of naturally occurring
genetic elements and the expression of only a small number of genes,
often only a single gene.15 7 The limited number of products, and the
relative simplicity of the underlying genetic constructs, reduces the
universe of patents that could potentially cover the product-and

153.
See, e.g., Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200 (Fed. Cir. 1991).
154.
See, e.g., Amgen, Inc. v. F. Hoffman-La Roche, Ltd., 580 F.3d 1340 (Fed. Cir. 2009).
155.
See Chugai Pharm., 927 F.2d 1200.
156.
See Dov Greenbaum, New Rules, Different Risk: The Changing Freedom to Operate
Analysis for Biotechnology, 11 N.C. J.L. & TECH. 139, 140 (2010).
157.
See Endy, supra note 1, at 23:00.
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processes and reagents used in making the product-thus containing
the scope of the freedom to operate analysis.
When a freedom to operate issue does arise, a conventional
biotechnology company can in many cases resolve it by in-licensing a
potentially infringed patent, or perhaps by designing around the
patent. 15 8 But even if the patent cannot be licensed or designed
around, the possibility of being sued for patent infringement does not
normally deter a conventional biotechnology company from attempting
to bring a potential blockbuster product to market. The company
understands that developing blockbuster drugs is a high-stakes
gamble with a high probability of failure; therefore, freedom to operate
is normally irrelevant since unsuccessful products rarely provoke
infringement lawsuits. On the other hand, if the product is successful,
the resulting profits should outweigh the cost of defending against a
patent infringement lawsuit. Indeed, patent infringement litigation is
almost inevitable for a company that has succeeded in bringing a
blockbuster product to market and should be considered part of the
price of success.
One particularly negative aspect of patents is the long lag time
between filing a patent application and the issuance of a patent, which
is typically several years, or even longer in some cases, particularly
when it becomes necessary to appeal an examiner's rejection. For
conventional biotechnology companies, the lag time is not necessarily
unduly problematic, given that it typically takes many years to bring
products like drugs and genetically modified plants to market. In fact,
delays in the issuance of a patent on a product that takes a long time
to bring to market can actually benefit the patent owner by pushing
forward the expiration date of the patent. This was clearly the case
under the old rules of patent duration, pursuant to which the patent
term extended seventeen years from the date the patent issued. 159
Even under the current rules, which provide that patents normally
expire twenty years after the date the application was filed,
extensions are available to compensate for delay in FDA approval and
for delays in prosecution attributable to the PTO, either of which can
result in patent terms extending well beyond twenty years from the
filing date. 160

158.
See Katherine J. Strandburg, What Does the Public Get? Experimental Use and the
Patent Bargain, 2004 WIS. L. REV. 81 (2004).
159.
See 35 U.S.C. § 154 (1994), amended by Uruguay Round Agreements Act, Pub. L.
No. 103-465, §534, 108 Stat. 4809, 4984 (1994).
160.
See 35 U.S.C. §§ 154, 156 (2012).
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C. Government Regulation and Trade Secret Law as Barriersto
CompetitorMarket Entry
Conventional biotechnology companies can benefit from various
non-patent barriers to competition that can function as alternates or
supplements to patents, including trade secret law and government
regulation. In some cases, the interplay of trade secret protection and
strict regulation can effectively block competition, even in the absence
of patent protection.
For example, trade secret law can provide effective protection
for processes used in the production of biotechnology products, so long
as the process is kept reasonably secret and marketing of the product
does not render the process susceptible to reverse engineering.16 1 In
biotechnology, it is often said that "the product is the process," because
the characteristics of a product produced in a living organism often
depend critically upon the specific methods and reagents used in its
manufacture. 162 With respect to a biologic drug, for example, a slight
change in the method of production could alter the product or
introduce contamination rendering the product ineffective, unsafe, or
even potentially deadly. 163 Thus, a competitor generally cannot make
a competing version of a recombinant human protein drug by simply
producing a protein having the identical amino acid sequence-unless
essentially the same process is used for manufacturing the protein,
there is no assurance that it would be pharmaceutically equivalent to
the original product.
With respect to recombinant therapeutic proteins, the stringent
FDA requirements for the marketing of biologic drugs have rendered
trade secret law a particularly potent form of IP. In order for another
company to gain approval to market a competing version of a
therapeutic protein, that company will, in most cases, be required to
provide FDA with all the necessary data to independently establish

161.
See Rockwell Graphic Sys. v. DEV Indus., 925 F.2d 174, 179 (7th Cir. 1991)
(describing adequate steps that may be taken to maintain secrecy); see also Kadant, Inc. v.
Seeley Machine, Inc., 244 F. Supp. 2d 19, 37-38 (N.D.N.Y. 2003) (holding that reverse
engineering does not constitute trade secret misappropriation).
162.
Joyce Wing Yan Tam, Biologics Revolution: The Intersection of Biotechnology, Patent
Law, and PharmaceuticalRegulation, 98 GEO. L.J. 535, 543 (2010) (internal quotation marks
omitted).
163.

See JUDITH A. JOHNSON, CONG. RESEARCH SERV., RL34045, FDA REGULATION OF

FOLLOW-ON BIOLOGICS 5 (2010); Huub Schellekens, Follow-on Biologics: Challenges of the 'Next
Generation',20 NEPHROLOGY DIALYSIS TRANSPLANTATION iv31, iv33-iv34 (2005).
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safety and efficacy. 164 FDA generally treats the data submitted by an
innovator to establish the safety and efficacy of its product as a trade
secret and will not rely on it to approve a competing product. 165 The
combination of trade secret protection and the high cost of generating
the data necessary to secure independent FDA approval create a
significant non-patent barrier to follow-on competition in the market
for protein therapeutics.
In an attempt to ease the regulatory burden facing prospective
developers of follow-on biologics, and thus to promote competition and
hopefully bring down the cost of these expensive drugs, Congress
enacted the Biologics Price Competition and Innovation Act of 2009
(BPCIA) as part of the larger health care reform package.1 66 The
BPCIA provides an abbreviated FDA approval process intended to
permit the sponsor of a biosimilar product to rely, at least in part, on
data submitted by an innovator when seeking FDA approval for the
biosimilar product. 167 It remains to be seen how effective the BPCIA's
abbreviated biosimilar pathway will be in lowering the regulatory
barrier to follow-on competition-there is some indication that the
process will still be quite expensive.1 68 Furthermore, at least one
innovator biopharmaceutical company has filed a petition with FDA
arguing that data the company submitted prior to the passage of
BPCIA is protected by trade secret law and thus cannot be used in the
approval of a potential competitor's follow-on product. 169
Some
companies have pulled back from their initial plans to develop
follow-on biologic products, due in part to the continuing opacity in
FDA's implementation of the Act. 170
In any event, the BPCIA provides a twelve-year period of data
exclusivity for innovators, during which time potential competitors are

164.
21 C.F.R. §§ 20.61, 701.3(a), 720.8 (2014); see Zotos Int'l, Inc. v. Young, 830 F.2d
350, 351 (D.C. Cir. 1987).
165.
See Citizen Petition Letter from Covington & Burling LLP, on behalf of Abbott
Labs., to U.S. Food & Drug Admin. (Apr. 2, 2012) [hereinafter Citizen Petition Letter], available
at http://op.bna.com/hl.nsf/id/jaqo-8twqhx/$File/AbbottCitizenPetition.pdf.
166.
See Patient Protection and Affordable Care Act, Biologics Price Competition and
Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-02, 124 Stat. 119, 804-21 (2010); Adelman
& Holman, supra note 69, at 566; Christopher M. Holman, MaintainingIncentives for Healthcare
Innovation: A Response to the FTC's Report on Follow-On Biologics, 11 MINN. J.L. Sci. & TECH.
755, 758 (2010).
167.
See Adelman & Holman, supranote 69, at 565.
168.
See, e.g., CONG. BUDGET OFFICE, COST ESTIMATE: S. 1695, BIOLOGICS PRICE
COMPETITION AND INNOVATION ACT OF 2007, at 6 (2008), available at http://www.cbo.gov/sites/

default/files/s1695.pdf.
169.
See Citizen Petition Letter, supra note 165.
170.
See Christopher Weaver et al., Biotech Drugs Still Won't Copy, WALL ST. J., Feb. 26,
2013, http://online.wsj.com/news/articles/SB10001424127887323864304578318111144984632.
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precluded from relying on the abbreviated pathway.17 1 The interplay
of trade secret and FDA regulation will thus continue to constitute a
substantial non-patent barrier to competition.
Government regulation, bolstered by trade secret law, can also
provide innovators in agricultural biotechnology with a substantial
non-patent barrier to competition. 172
As is the case with
pharmaceuticals, the regulatory agencies typically treat data
submitted in support of regulatory approval of agricultural
biotechnology products as trade secrets and will not rely on the
information to approve a competing company's product. 173 This puts
potential competitors of innovative agricultural biotechnology
companies in a position similar to that of would-be developers of
follow-on biologic drugs. Of course, the difference is that with respect
to agriculture, Congress has yet to create a statutory mechanism by
which follow-on competitors are able to take advantage of data
submitted by innovators.
IV. THE SYNTHETIC BIOLOGY REVOLUTION

In 2010, a team of scientists led by Craig Venter captured the
world's attention by reporting the successful synthesis of a functional
bacterial genome composed entirely of synthetic DNA. 174
This
scientific tour de force brought the burgeoning field of synthetic
biology to the policy forefront, prompting President Obama to impanel
a bioethics commission to study the potential benefits and risks of
synthetic biology and issue recommendations regarding "any actions
the Federal government should take to ensure that America reaps the

171.
See Henry Grabowski et al., Data Exclusivity for Biologics, 10 NATURE REV. DRUG
DISCOVERY 15, 15 (2011).
172.
See PHILLIPS MCDOUGALL, CROPLIFE INT'L, GETTING A BIOTECH CROP TO MARKET:
THE COST AND TIME INVOLVED IN THE DISCOVERY, DEVELOPMENT AND AUTHORISATION OF A NEW
PLANT BIOTECHNOLOGY DERIVED TRAIT 12 (2011), available at https://croplife.org/wp-

content/uploads/2014/04/Getting-a-Biotech-Crop-to-Market-Phillips-McDougall-Study.pdf;
Nicholas Kalaitzandonakes et al., Compliance Costs for Regulatory Approval of New Biotech
Crops, 25 NATURE BIOTECHNOLOGY 509, 509 (2007); Jamie K. Miller & Kent J. Bradford, The
Regulatory Bottleneck for Biotech Specialty Crops, 28 NATURE BIOTECHNOLOGY 1012, 1012
(2010).
173.
See The USDA Advisory Committee on Agricultural Biotechnology: SEHN's
Recommendations to the USDA,
http://www.sehn.org/usda.html.
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benefits of this developing field of science while identifying
15
appropriate ethical boundaries and minimizing identified risks."v
The resulting Presidential Commission's Report, released in
2010, essentially concluded that while potential risks arising from
advances in synthetic biology should be monitored and managed, the
likely benefits to society appear to be substantial.1 76 With respect to
the role of IP in advancing the field, the Commission "offer[ed] no
specific opinion on the effectiveness of current intellectual property
practices and policies in synthetic biology," but noted that
"[iintellectual property issues in synthetic biology are evolving" and
"that there are important concerns that deserve ongoing attention,
especially as this rapidly developing field evolves."' 77 The Report
advised the government to "keep careful watch on this field and
consider best practices and other policy guidance, if needed, to ensure
that access to basic research results and tasks is not unduly
limited." 78
Before going any further, this Section will attempt to define the
term "synthetic biology" and to explain the distinction between
synthetic biology and conventional biotechnology. In a nutshell, the
term "synthetic biology" has been coined to distinguish some of the
latest advances in genetic engineering from the "conventional
biotechnology" that has developed over the last forty years. Synthetic
biology differs from conventional biotechnology in a variety of
respects, including the use of powerful new tools for studying,
designing, and constructing new biological components such as DNA,
and an increased reliance on advanced principles of engineering in the
design of synthetic genetic sequences, organisms, and systems.1 79
One
commentator
has
suggested
that
conventional
biotechnology is less "genetic engineering" than it is "genetic
gardening," since the complexity of biological systems remains beyond
complete human control and outside the predictability one normally
associates with "engineering." 8 0 In contrast, synthetic biology aspires
to a substantially greater degree of predictability and control, much
more akin to true engineering. Synthetic biology is characterized by

175.
Jeffery Mervis, Obama Orders Review of Synthetic Biology, SCIENCE (May 20, 2010,
6:57 PM), http://news.sciencemag.org/2010/05/obama-orders-review-synthetic-biology
(internal
quotation marks omitted).
176.

See PRESIDENTIAL COMM'N FOR THE STUDY OF BIOETHICAL ISSUES, supra note 73, at

56, 113.
177.
Id. at 121.
178.
Id.
179.
See FAQ, SYNTHETIC BIOLOGY, http://syntheticbiology.org/FAQ.html (last visited
Feb. 25, 2014).
180.
See CHARLES, supra note 7, at 33 (internal quotation marks omitted).
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an increased reliance on chemically synthesized DNA, rather than the
cloned copies of naturally occurring DNA, and the use of standardized
and automatable processes as opposed to conventional biotechnology's
labor-intensive and empirical approaches to genetic design. 181 In a
sense, synthetic biology represents the natural evolution of
biotechnology from a largely empirical science based on trial-and-error
experimentation to a more predictable discipline driven by principles
of design and engineering. Synthetic biologists aspire to advance the
capabilities of genetic engineering to a point where the development of
engineered DNA capable of reprogramming "biological machines" will
employ the same principles of engineering currently used in the
development of the software used to program non-biological machines,
i.e., computers. 182
It is important to recognize there is no bright-line demarcation
between conventional biotechnology and synthetic biology. Synthetic
biology is more properly viewed as the next iteration in the evolution
of biotechnology than as an entirely discrete discipline. For example,
as discussed above, since the earliest days of biotechnology,
conventional biotechnologists have introduced minor modifications
into naturally occurring genetic sequences for purposes such as
improving recombinant protein expression in a foreign host cell, or to
slightly alter the amino acid sequence of the encoded protein. They
have also recombined naturally occurring genetic elements by, for
example, putting the expression of a recombinant gene under the
control of an inducible promoter. But the extent of the modifications
that characterize synthetic biology are of a different order of
magnitude. Instead of "merely tweak[ing]" the structures of the
naturally occurring genes, a genetic construct produced by synthetic
biology can comprise wholly synthetic genes that encode proteins
having structures and functions very different from anything that
occurs in nature. 18 3 The extent of divergence from naturally occurring
DNA sequences, the level of predictability and control, and the sheer
complexity of the resulting engineered DNA are what serve to
distinguish synthetic biology from conventional biotechnology.
While conventional biotechnologists have focused primarily on
expressing one, or at most several, recombinant proteins in a foreign
cell or organism, the aspirations of synthetic biologists have become

181.
See Drew Endy, Foundationsfor EngineeringBiology, 438 NATURE 449, 450 (2005).
182.
See id. at 449, 452.
183.
Matthew Herper, Photoshop for DNA, FORBES (June 1, 2005, 6:00 AM),
http://www.forbes.com/2005/06/01/cx-mh_0601dna.html. For an example of a synthetic protein,
see Linda A. Castle et al., Discovery and Directed Evolution of a Glyphosate Tolerance Gene, 304
SCIENCE 1151 (2004), available at http://www.sciencemag.org/content/304/5674/1151.abstract.
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much more ambitious.18 4 Synthetic biologists are reengineering the
operation of living cells by introducing a large number of distinct
interacting genes and genetic regulatory elements, resulting in a
fundamentally altered cellular metabolism.18 5
In some cases,
synthetic biologists are relying on entirely synthetic genes and genetic
elements and using these synthetic genetic constructs to produce
proteins and regulatory systems with no naturally occurring
counterpart.1 86 Instead of merely causing a microorganism to produce
high levels of a human protein and harvesting that protein from a cell
culture, synthetic biology can be employed to usefully alter the
metabolism of a microorganism, for example, to produce renewable
fuel from bulk cellulose, or a high-value pharmaceutical from low-cost
feed reagents, or to function as a biosensor that emits light in the
presence of a specific pathogenic bacterium.187
In fact, thanks to advances in synthetic biology, engineered
DNA is taking on more and more of the attributes traditionally
associated with computer software. 88 Like software, engineered DNA
is a coded set of instructions directed towards a "machine"-albeit a
biological machine-which causes the machine to perform useful
functions.18 9 In the case of both software and engineered DNA, an
engineer achieves a desired functional outcome by designing the code
used to control the machine, rather than by altering the mechanical
function of the machine itself. Just as software is the heart of a
computer-implemented functionality, the code embodied in engineered
DNA lies at the heart of a genetically engineered organism.
Significantly, as is the case with software, engineered DNA can
be used as the template for the production of an unlimited number of
virtually perfect digital copies of itself. Because each copy can serve
as the template for further copying, DNA and software are both highly

184.
See Applications, SYNTHETIC BIOLOGY, http://syntheticbiology.org/Applications.html
(last visited Apr. 5, 2014).
185.
See Eriko Takano & Rainer Breitling, Natural Products: Tools and More, 2 ACS
SYNTHETIC BIOLOGY 352, 352 (2013), available at http://pubs.acs.org/doi/full/10.1021/sb400O63n.
186.
See, e.g., Overview of XTEN, AMUNIX, http://www.amunix.com/technology/ (last
visited Nov. 12, 2014).
187.
See Ahmad S. Khalil & James J. Collins, Synthetic Biology: Applications Come of
Age, 11 NATURE REV. GENETICS 367, 377 (2010) ("By addressing such challenges, we will be
limited not by the technicalities of construction or the robustness of synthetic gene networks but
only by the imagination of researchers and the number of societal problems and applications that
synthetic biology can resolve.").
188.
See Ernesto Andrianantoandro et al., Synthetic Biology: New Engineering Rules for
an Emerging Discipline, 2 MOLECULAR SYs. BIOLOGY 1, 1 (2006), available at
http://www.ncbi.nlm.nih.gov/pme/articles/PMC1681505/.
See id.
189.
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susceptible to viral replication. 190
Viral replication can be a
technological advantage, but it also represents a huge point of
vulnerability to piracy.' 9 ' To the extent advances in DNA sequencing
and synthesis technologies minimize the technological barrier to
unauthorized replication of engineered DNA, the availability of IP to
provide an effective legal barrier to unauthorized copying becomes
increasingly critical, as discussed in more detail below. 192
A. DistinguishingCharacteristicsof Synthetic Biology Products and
Companies
The ascent of synthetic biology is spawning new companies
that do not fit the traditional paradigm of biotechnology. Synthetic
biology companies are moving beyond conventional biotechnology's
focus on recombinant proteins and genetically modified row crops and
attempting to commercialize a diverse array of other products and
services.1 93 As mentioned earlier, a number of synthetic biology
companies are seeking to develop and commercialize synthetic
organisms and biological systems engineered to produce biofuels and
other renewable energy sources. Other areas of focus include the
application of synthetic biology to the sustainable production of
structural materials such as bio-based plastics, or to the development
of biodetectors, which could represent an economical and effective
approach to monitoring for toxic residues and pathogenic agents in the
environment.194
Historically, the dominant business paradigm of conventional
biotechnology has centered on the development of a relatively small
number of highly profitable blockbuster products.
The move to
synthetic biology will likely cause a shift in the paradigm, tending
towards the development of a larger number of products, but fewer
blockbusters. As a consequence, the potential upside markets for the
products of synthetic biology will in many cases pale in comparison to

190.
In this context, the term "viral replication" is used to refer to the sort of replication
that, like the replication of viruses, involves the rapid and largely autonomous production of
multiple exact copies that themselves serve as the template for the production of multiple exact
copies, resulting in exponential amplification.
191.
Christopher M. Holman, Copyright for Engineered DNA: An Idea Whose Time Has
Come?, 113 W. VA. L. REV. 699, 737 (2011); see Brief of Amicus Curiae Law Professor Christopher
M. Holman in Support of Respondents, Bowman v. Monsanto Co., 133 S. Ct. 1761 (2013) (No. 11796), 2013 U.S. S. Ct. Briefs LEXIS 459 [hereinafter Brief of Holman].
192.
Holman, supra note 191, at 720.
193.
See Khalil & Collins, supra note 187, at 377.
194.
See infra Part IV.B-C.
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the lucrative markets targeted by conventional biotechnology
companies. 195 There are a number of factors that will drive this trend.
For one thing, synthetic biology products that are not human
drugs or major agricultural traits will likely be less profitable than the
primary products of conventional biotechnology. 196 As discussed
below, many synthetic biology companies are benefiting from federal
and private grants awarded to fund various product development
projects. While this is surely a welcome form of revenue for the
companies, it seems reasonable to surmise that at least part of the
reason the federal government and private philanthropic granting
agencies provide money to support these projects is a feeling that the
perceived profitability of these ventures is insufficient to generate the
necessary private investment to fund such projects.
Another factor that will likely reduce the upside potential for
profitability is an anticipated decentralization of the research and
development process.1 97
Pioneering biotechnology companies like
Genentech and Amgen were built on the model of the vertically
integrated full-service pharmaceutical company, whereby a single firm
executes the entire drug commercialization process from initial
research and development to FDA approval and marketing. 198
Because these various functions are conducted under the same
corporate roof, a single company is able to capture the bulk of the
upside profit potential that flows from the development of a
blockbuster drug.
In contrast, one of the foundational premises of the synthetic
biology movement is that the efficiency of biological engineering can
be greatly improved by a more modular approach to product
development involving collaboration between individuals and firms
specializing in a specific aspect of synthetic biology. 9 9 As Professor
Drew Endy has pointed out, this division of labor will allow a
specialist genetic engineer to design complex genetic systems at a high
level of abstraction, while leaving the details of actually synthesizing
195.
See Rob Carlson, On the Demise of Codon Devices, SYNTHESIS (Apr. 15, 2009),
http://www.synthesis.cc/2009/04/on-the-demise-of-condon-devices.html (noting that the market
for the products of synthetic biology companies is orders of magnitude smaller than the market
for the products of 'old style' recombinant DNA").
196.
Drugs in particular tend to have unusually high margins. PharmaceuticalIndustry,
WORLD HEALTH ORG., http://www.who.int/trade/glossary/story073/en/ (last visited Nov. 12, 2014)
(stating that many large drug companies see profit margins of about 30 percent).
197.
See Endy, supra note 181, at 451 ("The decoupling of design and fabrication in
biological engineering is being driven by recent and ongoing improvements in the process of DNA
synthesis.").
198.
About Amgen, AMGEN, http://www.amgen.com/about/overview.html (last visited Apr.
5, 2014); About Us, GENENTECH, http://www.gene.com/about-us (last visited Apr. 5, 2014).
199.
See Endy, supra note 181, at 451.
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the full-length DNA molecule, and in some cases its smaller
constituent elements, to other individuals more specialized in the
performance of that task. 2 0 0 For example, a firm specializing in
genetic engineering at a higher level of abstraction could outsource the
design and assembly of component genetic elements to a second firm
that is focused on engineering DNA at a lower level of abstraction.
This second firm might, in the same manner, contract out the actual
synthesis of the DNA molecules to a third firm specializing in DNA
synthesis. While this division of labor should greatly improve the
efficiency of the product development process, it will inherently tend
to dilute the potential upside profitability for many of the
participating firms.
Instead of individual firms focusing on the cradle-to-market
development of a small number of products, specialist synthetic
biology companies can focus on developing an extremely efficient core
competency and applying that competency to a relatively large
number of different projects. This can be done in collaboration with a
variety of other firms that, in turn, bring their own core competencies
to bear on the problem to be addressed. This disaggregation and
dispersion of labor and investment should increase the probability of
synthetic biology companies succeeding in creating commercially
successful products, in contrast with the relatively high failure rate of
conventional biotechnology companies pursuing a blockbuster model.
By the same token, however, the upside potential for companies
participating in collaborative product development will be diluted by
the fact that the profits flowing from a successful product will be
divided amongst all of the companies that participated in the project.
Pushing this point to the extreme, some synthetic biology
companies will perform their services for a flat payment without
obtaining any equity position in a resultant commercial product. For
example, a firm specializing in DNA synthesis will in most cases
simply charge their customers for the synthesis of the DNA and will
generally not ask for any percentage of the profits that might accrue
from a resulting product. 201 On the one hand, this sort of contract
work provides a sure source of revenue for the DNA synthesis
company, but it also eliminates the potential for large upside
profitability, which drives the prevailing business model for
conventional biotechnology.
While product development in synthetic biology will likely have
less upside profit potential, it should be easier and less expensive to
bring the products of synthetic biology to market than has been the
200.
201.

See id.
Author's personal communication with Claes Gustafsen, a founder of DNA2.0.
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case with respect to conventional biotechnology. The barriers to
commercialization facing synthetic biology companies should be
substantially less than those conventional biotechnology companies
have dealt with, and more in line with those facing a company
developing a typical non-biotechnology product. Significantly, the
products of synthetic biology should generally face substantially lower
regulatory barriers to market entry than the products of conventional
biotechnology. Many of the products of synthetic biology will be
synthetic microorganisms and non-medicinal products produced using
these microorganisms, such as fuel or bio-based structural
materials. 20 2 The time and expense entailed in obtaining regulatory
approval for the commercialization of these microorganisms and
products should be relatively modest, particularly if the
microorganism is to be used under contained conditions, as will often
be the case when microorganisms are used in the production of
non-pharmaceutical chemicals. Many of the regulatory burdens facing
agricultural biotechnology companies arise out of concerns that a
genetically engineered plant might "escape" and propagate
uncontrollably in the wild, a concern that is greatly ameliorated when
the genetically engineered organism is only used under contained and
controlled conditions. 203
While various federal regulations apply to synthetic biology,
many synthetic biology products are unlikely to implicate drug, food,
or agricultural safety, and will thus avoid burdensome FDA and
USDA oversight. EPA regulations will likely constitute the most
substantial regulatory barrier to commercialization. But under the
Toxic Substances Control Act (TSCA), the EPA is only authorized to
require a limited amount of information to assess the risks posed by
genetically
engineered
microorganisms. 2 0 4
For
instance,
manufacturers are generally not required to test for toxicity,

202.
See Khalil & Collins, supra note 187, at 367.
203.
See Plant Protection Act, 7 U.S.C. § 7701-7786 (2012). The Act provides that the
Secretary of the US Department of Agriculture may issue regulations to "prevent the
introduction of plant pests into the United States or the dissemination of plant pests within the
United States." Id. § 7711(a). The Secretary has delegated that authority to the Animal and
Plant Health Inspection Service (APHIS). 7 C.F.R. §§ 2.22(a), 2.80(a)(36) (2014). APHIS has
promulgated regulations governing the introduction of organisms and products altered or
produced through genetic engineering that are, or are believed to be, plant pests. 7 C.F.R. §
340.0(a)(2) (2014). Under these regulations, many genetically engineered plants are presumed to
be plant pests and are thus strictly regulated under the Act. 7 C.F.R. §§ 340.1, 340.2, 340.6
(2014).
PRESIDENTIAL COMM'N FOR THE STUDY OF BIOETHICAL ISSUES, supra note '73, at 93.
204.
See also Biotechnology, U.S. ENVTL. PROTECTION AGENCY, http://www.epa.gov/oppt/biotech/
index.htm (last visited Apr. 5, 2013).
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pathogenicity, or other harmful effects prior to submitting a
notification to the EPA. 2 0 5
In situations where a synthetic organism is intended for use in
an uncontained manner, raising the possibility of an uncontrolled
release into the environment, it will typically be engineered so that it
cannot reproduce on its own, thereby reducing public health and
environmental concerns and ameliorating the need for stringent
regulatory oversight. 206 In any event, experience has shown that
synthetic cells and organisms engineered to function under controlled
conditions have consistently evolved toward non-functionality,
rendering them short-lived in a natural environment. 207
Another significant distinction between synthetic biology and
conventional biology is that the former will be much more likely to
periodically update their products and processes.
The long time
frames associated with developing conventional biotechnology
products, and particularly the strict regulatory approval requirements
pertaining to drugs and recombinant plants, tend to lock in the
features of those products at a relatively early stage of product
development.
For example, once a protein pharmaceutical has
achieved FDA approval, even a relatively minor alteration in the
products and processes might necessitate an additional round of
regulatory
approval,
which
would
be
expensive
and
time-consuming. 2 0 8
Similar constraints apply to recombinant
agriculture, since introduction of a new trait in field-ready crop plants
takes years and will generally require new regulatory approval, not
only in the United States but also in foreign markets that might
impose stricter regulations on genetically modified crops. 209
In
contrast, a synthetic biology company using a synthetic organism to
produce a fuel or chemical would generally face few regulatory
obstacles to switching to an improved organism-particularly if the
change does not alter the final product and the organism is used under
controlled conditions or otherwise does not present safety or
environmental issues based on risk of escape into the environment.

205.
See Microbial Products of Biotechnology; Final Regulation Under the Toxic
Substances Control Act, 62 Fed. Reg. 17,910 (Apr. 11, 1997) (to be codified at 40 C.F.R. pts. 700,
720, 721, 723, 725).
206.

PRESIDENTIAL COMM'N FOR THE STUDY OF BIOETHICAL ISSUES, supra note 73, at 63,
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207.
Id. at 70.
208.
See 21 C.F.R. § 601.12 (2014).
209.
See Regulatory Impact Analysis for the Regulation of Microbial Products of
Biotechnology:
International Considerations, U.S.
ENVTL.
PROTECTION
AGENCY,
http://www.epa.gov/biotech-rule/pubs/ria/ria028.htm (last updated Sept. 27, 2012).

2015]

DEVELOPMENTS IN SYNTHETIC BIOLOGY

427

and
a company that has developed
For example,
commercialized an organism engineered to function as a biosensor
will, in all likelihood, identify additional markets for variants of the
original product, such as a biosensor directed toward a different
microorganism, or one able to sense the microorganism in a different
environment or medium such as water or blood. Alternatively, the
company might simply come up with an improved version of its
original product.
Synthetic biology companies will likely release
multiple iterations of their products, with "2.0" and "3.0" versions
analogous to the updated products routinely offered by software
companies.
Finally, another important aspect of the synthetic biology
revolution is the increasing role of amateur user-innovators and
do-it-yourselfers (DIY) in the innovation process, a development made
possible by advances in the technology that substantially reduce the
barrier to entry for non-specialists. 2 10 This will be a dramatic
departure from the paradigm of conventional biotechnology, where
innovation has largely been limited to dedicated biotechnology
companies and well-funded academic laboratories. It is anticipated
that many of the contributions of amateur DIY synthetic biologists
will arise in the context of collaboration and open source, in a manner
analogous to the role played by hackers and open innovation in
software development. 211 Amateur synthetic biologists have already
succeeded in conceiving of and executing on the development of novel
synthetic biology products that rival the successes of professional
biotechnologists, as discussed later in this Part.
The evolving business model of synthetic biology will in all
likelihood result in substantially different IP imperatives for the
various actors as compared to those facing firms engaged in
conventional biotechnology research and development.
This
divergence in IP imperatives is the focus of Part V of this Article. But
as a prelude to this discussion, and in order to provide a more concrete
sense of the nature of the synthetic biology revolution, this Part
concludes by surveying some specific examples of companies and
individuals currently engaged in the synthetic biology movement to
serve as case studies illustrating the evolution of the biotechnology
paradigm.

210.
See Endy, supra note 181, at 452.
211.
See Nathaniel Johnson, Steal This Genome!, EAST BAY EXPRESS (Mar. 30, 2005),
http://www.eastbayexpress.com/ebx/steal-this-genome/Content?oid=1077148.
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B. Companies Using Synthetic Biology to Produce Synthetic Proteins
Synthetic biology companies are attempting to commercialize
synthetic proteins that diverge substantially from any naturally
occurring counterpart, in terms of both chemical structure and, more
importantly, functionality. 2 12
These companies are also moving
beyond conventional biotechnology's focus on the application of genetic
engineering to agriculture and health care. This Section profiles a few
of the companies that have been on the leading edge of this aspect of
the synthetic biology revolution.
One of the pioneering companies in the development of proteins
reengineered for enhanced function has been Genencor. 2 13 Although
Genencor began as a spin-off from a prototypical conventional
biotechnology company, over time its approach to product
development has continuously moved toward the ideal of synthetic
biology.21 4 In fact, long before the term "synthetic biology" came into
vogue, the company employed the tools of conventional biotechnology
to modify the amino acid sequence of naturally occurring proteins in
order to produce industrial enzymes with improved functional
characteristics such as increased catalytic activity, enhanced stability,
or altered temperature dependence.
For example, Genencor developed a genetically engineered,
thermostable alpha-amylase marketed under the trade name
Spezyme. 215 The enhanced thermostability of the Genencor product
relative to the naturally occurring enzyme was accomplished by
means of a single amino acid substitution in the enzyme's protein
sequence and results in increased catalytic efficiency. 216 While the
extent of the structural modification is quite minimal, the
reengineering of a natural protein sequence to achieve enhanced
function at least represents a move towards the aspirations of
synthetic biology. With continuing advances in the capabilities of
synthetic biology, the trend is toward the development of synthetic
proteins with structures that deviate much more substantially from
212.

See PRESIDENTIAL COMM'N FOR THE STUDY OF BIOETHICAL ISSUES, supra note 73, at

65.
213.
See supra notes 54-56 and accompanying text.
214.
Pathway Engineering, DUPONT, http://biosciences.dupont.com/duponttm-genencorrscience/production/pathway-engineering/ (last visited Apr. 5, 2014).
215.
Alpha-amylase is a naturally occurring enzyme used in bio-based processes for
catalyzing the conversion of corn into fuel ethanol. See Press Release, Genencor, Genencor
Launches New Enzyme for Ethanol
Production (June 14, 2010), available at
http://www.prnewswire.com/news-releases/genencor-launches-new-enzyme-for-ethanol-

production-96281583.html.
216.
See Novozymes A/S v. DuPont Nutrition Biosciences APS, 723 F.3d 1336, 1341 (Fed.
Cir. 2013).
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any naturally occurring precursor and which are imbued with
functionality that is qualitatively distinct from anything to be found in
nature.
Consider Maxygen, for example-a company founded in the
1990s to commercialize "DNA shuffling," a powerful technological
platform for the development of novel synthetic genes and proteins. 217
The company's initial business plan focused on applying DNA
shuffling to the development of products targeting a wide array of
market opportunities, including not only human drugs and vaccines,
but also agriculture and bio-based synthesis of high-value
chemicals. 218 Maxygen has used DNA shuffling to generate synthetic
DNA sequences that encode novel proteins that deviate substantially
from anything found in nature, in terms of both structure and
function. This substantial divergence from any corresponding native
DNA sequence distinguishes the Maxygen technology from the more
limited approach to protein engineering exemplified by Genencor's
creation of Spezyme by modifying a single amino acid in otherwise
native alpha-amylase.
One of Maxygen's early successful applications of DNA
shuffling arose out of the company's agricultural division, which had
been tasked with developing a gene capable of conferring glyphosate
resistance on plants, i.e., to create the functional equivalent of
Monsanto's Roundup Ready trait.2 19 In a scientific tour de force,
Maxygen scientists used DNA shuffling to create a synthetic gene
encoding a novel protein capable of metabolizing glyphosate, which
they christened glyphosate acyl-transferase (GAT). 220 Although GAT
is based on the amino acid sequences of naturally occurring proteins,
its amino acid sequence diverges substantially from any naturally
occurring protein, and the protein's functional ability to metabolize
glyphosate far exceeds anything found in nature. 2 21 The GAT
technology was acquired by Pioneer Hi-Bred, a subsidiary of DuPont,

217.
Essentially, DNA shuffling is a synthetic, human-directed process that attempts to
mimic and accelerate natural evolution. CHARLES, supra note 7, at 298. The term "DNA
shuffling" has come to encompass a variety of related methodologies for achieving the directed
molecular evolution of genes, proteins, and organisms. Id.
218.
The author is a former employee of Maxygen, and much of the discussion of
Maxygen is based on personal knowledge.
219.
See supra note 217.
220.
Linda A. Castle et al., Discovery and Directed Evolution of a Glyphosate Tolerance
Gene, 304 SCIENCE 1151, 1151 (2004).
221.
Id. at 1152-53.
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and in 2008 the company received US regulatory approval to use the
GAT trait in soybeans. 222
Another exemplar of the new breed of synthetic biology
company, Amunix, has moved even further along the spectrum
towards the ultimate aspirations of synthetic biology. Amunix was
founded by William "Pim" Stemmer, the inventor of Maxygen's
original DNA shuffling technology. 2 2 3 The company's business model
focuses on the development of synthetic proteins that are not based on
any naturally occurring protein, expanding upon the concept of
synthetic protein design to the point of true de novo protein
engineering. 224 Amunix predicts that its approach to synthetic biology
will prove useful in improving the pharmaceutical characteristics of
protein therapeutics. 2 2 5
C. Companies Using Synthetic Biology to Manufacture Non-Protein
Chemicals
When one considers the range of potential commercial
applications of genetic manipulation, engineering a cell to produce a
recombinant protein is a relatively straightforward proposition. In
comparison, engineering a cell to produce a non-protein chemical
entity, such as a small molecule metabolite or natural product,
presents a much greater technical challenge. 226 One of the primary
objectives of synthetic biology is the development of synthetic
organisms engineered to produce high-value small molecule
metabolites, e.g., fine chemicals such as pharmaceuticals, or
pharmaceutical precursors, or chemicals useful as a source of energy
or structural material, such as ethanol or a plastic precursor. 227
The biological synthesis of non-protein molecules in engineered
organisms is achieved by means of metabolic pathways that comprise
multiple interacting proteins, and these proteins must work together

222.
DuPont Receives Approval for Optimum GAT Soybean Trait, CROP BIOTECH UPDATE
(July
25,
2008),
available
at
http://www.isaaa.org/kc/cropbiotechupdate/article/
default. asp?ID=2 863.
223.
About Us, AMUNIX, http://www.amunix.com/content/about/index.htm (last visited
Apr. 5, 2014).
224.
Volker Schellenberger, A Recombinant Polypeptide Extends the In Vivo Half-life of
Peptides and Proteins in a Tunable Manner, 27 NATURE BIOTECHNOLOGY 1186, 1189 (2009). See
also U.S. Patent No. 7,855,279 (filed Mar. 6, 2007).
225.
See Overview of XTEN, supra note 186.
226.
Takano & Breitling, supra note 185, at 352.
227.
Id.; see also Current Uses of Synthetic Biology: Naturally Replicating Rubber for
Tires, BIOTECHNOLOGY INDUSTRY ORG. (July 26, 2011), http://www.bio.org/articles/current-usessynthetic-biology.
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practical matter, it has proven quite difficult for synthetic biologists to
genetically engineer microbial metabolic pathways, in part because of
a variety of positive and negative feedback mechanisms that tend to
compensate for genetic alterations to an organism's metabolism. 229
Altering the function of a metabolic enzyme, or introducing a novel
metabolic enzyme into a microbe, can cause dramatic changes in the
expression and function of other metabolic enzymes within that
microbe, often thwarting the best laid plans of a synthetic biologist
intent upon reengineering the microbial metabolism to achieve some
useful end. 23 0

In spite of the challenges, advances in synthetic biology have
increasingly rendered it feasible to engineer the metabolism of a
microorganism to produce commercial quantities of a desired
non-protein chemical. In some cases, a synthetic biology company
might do so with the intent of selling the engineered microorganism to
another company that would use it in their own production processes.
For example, a pharmaceutical company might be interested in
purchasing a genetically engineered synthetic microbial process for
producing a drug active ingredient, perhaps as a less expensive and
chemical
synthesis. 231
to
conventional
alternative
greener
Alternatively, a synthetic biology company might choose to exploit the
commercial attributes of an engineered microorganism internally,
using it to produce a valuable chemical product for commercial sale.
Codexis, a 2002 spin-off of Maxygen, is a prime example of a
company engaged in this commercial aspect of synthetic biology. 23 2
The company is actively engaged in engineering not only individual
genes and enzymes, but also entire organisms and metabolic
pathways. Codexis has obtained patents claiming technologies for
engineering whole cells and organisms in a manner that enhances
desired characteristics, such as the capacity to express or secrete
proteins and small molecule metabolites. 233 It has also patented

228.
229.

Takano & Breitling, supra note 185, at 352.
Gregory Stephanopoulos & Anthony J.

Sinskey,

Metabolic Engineering-

Methodologies and FutureProspects, 11 TRENDS BIOTECHNOLOGY 392, 392 (1993).

230.
Gregory
Stephanopoulos,
Metabolic Engineering, 5 CURRENT
OPINION
BIOTECHOLOGY 196, 196 (1994).
231.
See supra note 183 and accompanying text.
232.
Codexis has prospered and was the subject of a successful initial public offering in
2010. David R. Baker, Clean-tech IPO Brings $78 Million to Codexis, SFGATE (Apr. 23, 2010),
http://www.sfgate.com/business/article/Clean-tech-IPO-brings-78-million-to-Codexis3266769.php.
233.
See, e.g., U.S. Patent No. 8,076,138 (filed Oct. 15, 2009).
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technologies for engineering synthetic metabolic pathways in living
organisms. 234
Codexis prides itself on the "green" attributes of its
and
economical
provide
which
platforms,
technological
to traditional
environmentally friendly bio-based alternatives
chemical synthesis processes for the production of fine chemicals, fuel,
and plastics. 235 In 2006, Codexis was awarded the EPA's Presidential
Green Chemistry Challenge Award for successfully engineering a
synthetic metabolic pathway capable of producing a key intermediate
in the production of the important drug atorvastatin (Lipitor). 236 This
process employs three synthetic protein biocatalysts, which Codexis
developed using a proprietary form of DNA shuffling the company
refers to as "Molecular Breeding." 2 37
Codexis actively solicits grant money to support its research
For example, in 2010 the company
and development efforts.
announced that it had been selected to receive a $4.7 million grant
from the US Department of Energy to develop innovative biocatalysts
for achieving more efficient carbon capture from coal-fired power
plants. 2 38 This grant was provided under the ARPA-E 2009 American
Recovery and Reinvestment Act, which funds innovative energy
research. 239
Amyris is another example of a synthetic biology company
primarily focused on the development of synthetic microorganisms
useful in the production of valuable non-protein chemicals. Amyris
was founded by synthetic biologists at the University of California,
Berkeley seeking to use synthetic biology to "deliver impactful
solutions to the world's most significant problems." 240 One of their
reported successes has been the engineering of a synthetic microbe
capable of efficiently producing artemisinic acid, a precursor used in

234.
U.S. Patent No. 8,048,674 (filed Sept. 11, 2009).
From Achieving Three Coveted PresidentialGreen Chemistry Challenge Awards to
235.
Being Recognized as One of the Hottest Companies in Renewable Chemicals, We Have Earned
ConsiderableAccolades, CODEXIS, http://www.codexis.com/awards (last visited Apr. 6, 2014).
Press Release, Codexis, Codexis Awarded U.S. Environmental Protection Agency's
236.
available at
(June 26,
2006),
Presidential Green
Chemistry Challenge Award
http://ir.codexis.com/phoenix.zhtml?c=208899&p=irol-newsArticle&ID= 1181061&highlight.
Lipitor, one of the best-selling drugs in the world, is used to lower cholesterol. Id.
237.
Id.
238.
Press Release, Codexis, Codexis Awarded ARPA-E Grant for Carbon Capture Clean
Air Technology (May 3, 2010), available at http://ir.codexis.com/phoenix.zhtml?c=208899&p=irolnewsArticle&ID=1421019&highlight.
239.
Id.
240.
History, AMYRIS, http://www.amyris.com/Company/149/History (last visited Apr. 6,
2014) (quoting Jack Newman, co-founder of company).
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the production of the low-cost anti-malarial drug, artemisinin. 241
Funding for this project was provided through a grant from the Bill
Melinda Gates Foundation to the Institute for OneWorld Health. 242
Amyris has also granted Sanofi-Aventis, a large pharmaceutical
company, a royalty-free license to use this technology for the
production of artemisinin-based drugs, which hopefully will provide
substantial benefits to developing countries in desperate need of
accessible anti-malarial products. 243
Amyris has obtained patents on general methodologies useful
in engineering microbial genomes, including methods and reagents
useful in the targeted excision of a genetic locus from the genome of a
The company has also obtained patents covering
host cell. 2 4 4
For
engineered cells capable of producing high-value chemicals.
example, they have patents that claim synthetic cells engineered to
produce isoprenoids, a class of compounds useful as pharmaceuticals,
cosmetics, perfumes, pigments and colorants, fungicides, antiseptics,
nutraceuticals, and fine chemical intermediates. 245 They have also
obtained patent protection for engineered cells useful in the
production of terpenes, which are used as antibiotics, hormones,
anticancer drugs, insecticides, and chemicals. 246
Amyris's business model embraces a collaborative approach to
product development. As touted on the company's website, "we are
pragmatic enough to realize that many technology innovations that
will advance our mission may not happen within the walls of
Amyris." 247
In pursuit of this model, Amyris actively solicits
collaborative partnerships with other companies interested in
incorporating renewable,
synthetic biology-based
technologies
developed by Amyris into their production processes.
For example, in 2010, Amyris announced that it had entered
into a collaboration and joint development agreement with Firmenich,
the largest privately owned fragrance and flavor company in the
world. 24 8
Under the agreement, "Firmenich will fund technical

241.
Press Release, Amyris, Amyris Scientists Describe Breakthrough in Development of
Anti-Malarial Drug Precursor (Apr. 11, 2013), available at http://amyris.com/amyris-scientistsdescribe-breakthrough-in-development-of-anti-malarial-drug-precursor/.
242.
Id.
History, supra note 240.
243.
244.
U.S. Patent No. 7,919,605 (filed Dec. 23, 2010).
245.
See, e.g., U.S. Patent No. 8,257,957 (filed Sept. 25, 2007).
246.
U.S. Patent No. 8,236,512 (filed Feb. 1, 2012).
247.
Collaborations, AMYRIs, http://amyris.com/innovation/collaborations/ (last visited
Apr. 6, 2014).
248.
Press Release, Amyris, Amyris Enters into Collaboration and Joint Development
Agreement with Firmenich (Nov. 1, 2010), available at http://www.businesswire.com/news/home/
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development at Amyris to produce a sustainable, cost-effective and
reliable source of a key ingredient for the fragrance and flavor
market." 249 Amyris will manufacture and supply the product, while
Firmenich will market and distribute it. 2 50
In 2011, Amyris announced plans to launch a collaborative
venture with Wilmar International Limited: 251
The collaboration will focus on the development and worldwide commercialization of a
family of surfactants derived from Amyris BiofeneTM for use in a range of products,
including consumer packaged goods, personal care products and industrial applications.
The parties expect that these surfactants will be effective replacements for nonylphenol
ethoxylate surfactants (NPEs), the use of which is currently being phased out or
severely restricted by regulatory agencies around the world due to health and
environmental concerns.

252

Also in 2011, Amyris announced a collaboration with Michelin
to develop and commercialize renewable isoprene. 253 Isoprene is an
important chemical building block used in the production of rubber
tires and other products that use synthetic and natural rubbers. 254
Under the agreement, Amyris retains the right to market its
renewable isoprene to other customers. 255
D. Companies Using Synthetic Biology to Produce Useful Synthetic
Organisms
Some synthetic biology companies are attempting to
commercialize synthetic organisms endowed with novel and useful
One such company, Guild Biosciences, is
functional attributes.
engineering viruses and single celled organisms to function as
biosensors having the ability to detect and ameliorate a variety of
harmful agents in the environment. 256 The company's research efforts
have a number of highly useful applications and have benefited from
20101110007023/en/Amyris-Enters-Collaboration-Joint-Development-Agreement-Firmenich#.
VK2kworF9XY.
Id.
249.
Id.
250.
Press Release, Amyris, Amyris Expands into Asia and Global Surfactants Though
251.
Collaboration with Wilmar (June 23, 2011), available at http://www.packagingeurope.com/
Packaging-Europe-News/41580/Amyris-Expands-into-Asia-and-Global-Surfactants-ThoughCollaboration-with-Wilmar.html.
Id.
252.
Press Release, Amyris, Amyris and Michelin Announce Collaboration to Develop
253.
at
2011),
available
28,
(Sept.
Isoprene
Renewable
Commercialize
and
http://www.businesswire.cominews/home/20110928005133/en/Amyris-Michelin-AnnounceCollaboration-Develop-Commercialize-Renewable#.VK2s8YrF9XY.
Id.
254.
Id.
255.
256.

Biosensors

Research,

GUILD

biosensors research (last visited Nov. 12, 2014).

BIOSCIENCES,

http://www.guildbiosciences.com/
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funding by governmental agencies that include the National Institutes
of Health (NIH), the USDA, and the National Security Agency
(NSA).257
One aspect of Guild's approach is exemplified by their
development of bacteriophage biosensors capable of detecting specific
bacterial pathogens in food, human fluid, and environmental
samples. 258 To accomplish this, Guild scientists introduced genes
The
encoding bioluminescent proteins into the bacteriophage.
bioluminescent gene is activated in the presence of a specific bacteria
recognized by the bacteriophage, resulting in the production of light
that can be detected by a machine, or in some cases by the human
eye. 259 These biosensors are highly selective, only recognizing a
narrow range of bacterial targets and thus minimizing the likelihood
of a false positive. 260 Guild's bacteriophage technology could be used
in a variety of important applications, such as phytopathogen
diagnostics, to limit the impact of crop disease or as a means to detect
weaponized bacteria. 261 Significantly, the bacteriophage biosensors
being developed by Guild are engineered so that they will not
replicate, which should result in reduced regulatory barriers relative
to a conventional biotechnology product that might reproduce in the
wild, such as a genetically modified plant. 2 6 2

Guild's endeavors are not limited to synthetic bacteriophage.
For example, the company has genetically engineered a synthetic
yeast capable of functioning as biosensor-biocatalyst for the detection
and biodegradation of paraoxon, a poisonous organophosphate
pesticide some fear could be employed as a chemical weapon. 263 Guild
also hopes to use its technology to produce a synthetic organism that
can quickly and accurately diagnose anthrax or plague. 264
E. Gene Synthesis Companies
One manifestation of the disaggregation and modularization of
product development to which synthetic biologists aspire is the
increasing reliance on specialist firms for the synthesis of DNA, a
development that has been greatly facilitated by rapid advances in
257.
Id.
258.
Id. A bacteriophage is a form of virus that recognizes and attacks bacteria. Id.
259.
Id.
260.
Id.
261.
Id.
262.
Author's personal communication with an executive of Guild Biosciences.
263.
Chemical Warfare Defense, GUILD BIOSCIENCES, http://www.guildbiosciences.com/
chemicalwarfare-defense (ast visited Nov. 12, 2014).
264.
Biosensors Research, supra note 256.
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DNA synthesis technology. Until relatively recently, non-biological
DNA synthesis was, for the most part, limited to the production of
relatively short DNA sequences, and even the synthesis of a single
full-length gene was technically impracticable. In 2004, for example, a
10,000 base polynucleotide was about the limit of DNA synthesis
technology. 2 65 To obtain a full-length gene sequence, the conventional
biotechnologist was generally forced to clone the DNA from a natural
source, such as a genomic or cDNA library, often a tedious and
time-consuming process. 266 Today, however, advances in technology
have rendered it feasible to synthesize much longer DNA sequences on
the order of one million bases or more. 2 6 7 It has become routine to
synthesize whole genes and even large stretches of genomic DNA
comprising many genes and genetic elements. 268 Some entire small
genomes have even been synthesized de novo. 2 6 9
These advances in DNA sequencing technology have given rise
to dedicated gene synthesis companies able to synthesize long and
complex DNA molecules quickly and economically for their customers.
Custom gene synthesis services can be ordered online, allowing today's
synthetic biologists to outsource DNA synthesis and focus their
attention on the design and testing of synthetic DNA sequences. 270
The proliferation of DNA synthesis companies, coupled with dramatic
advances in DNA sequencing technology, has substantially lowered
the technical barrier for interconverting between the genetic sequence
as information and as physically embodied in a DNA molecule. 271 In
effect, the tools of synthetic biology are rendering DNA and genetic
sequence information fungible. 272
DNA2.0, headquartered about twenty miles south of Genentech
near the shores of San Francisco Bay, is a prime example of a
successful gene synthesis company. The company was founded in
2003 when a small group of former Maxygen employees decided to
start their own gene synthesis company-an ambitious endeavor

265.

Endy, supra note 1, at 23:00.

266.

See generally JOSEPH SAMBROOK ET AL., MOLECULAR CLONING: A LABORATORY

MANUAL chs. 8-9 (2d ed. 1989) (providing protocols for cloning of cDNA and genomic DNA).
267.
See Pennisi, supra note 174, at 958.
268.
Id.
269.
Id.
270.
Stephen Hilgartner, Novel Constitutions? New Regimes of Openness in Synthetic
Biology, 7 BioSOCIETIES 188, 197 (2012) ("The declining cost of DNA sequencing and synthesiswhich synthetic biologists see as analogous to Moore's law in computing-is also expected to
contribute to increasingly widespread availability of the tools to make new living things and
biological devices.").
Id.
271.
272.
Endy, supra note 1, at 25:00.
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initially funded by the founder's personal savings and lines of credit. 27 3
To this day, DNA2.0, a privately held corporation, has not accepted
any venture capital funding and its manufacturing facilities remain in
the United States. 274 It is also the largest US provider of synthetic
genes, with a global customer base comprising numerous firms
engaged in various pursuits, including research and product
development.2 75
DNA2.0's business involves much more than simply
synthesizing DNA for its customers. For example, the company
provides its customers with a suite of tools to assist them in
reengineering and designing genes and proteins to suit their
individual needs. DNA2.0 also assists customers in engineering
optimized protein sequences to achieve new and improved
functionality, or in designing new genetic constructs in order to alter
the metabolism of a microorganism. The company has even gotten
involved in whole genome design. As touted on their website,
"DNA2.0's tools and solutions are fueling the transformation of biology
from a discovery science to an engineering discipline."27 6
F. User-Innovatorsand Do-It-Yourself Genetic Engineers
Under the dominant paradigm of conventional biotechnology,
the design and manufacture of innovative biotechnological products
has typically been restricted to a relatively small group of professional
biotechnologists working in well-provisioned laboratories. However,
many believe that advances in synthetic biology will shift the
paradigm by providing powerful yet accessible tools that will
democratize innovation in biotechnology in a manner similar to what
has occurred online with the growth of the Internet. Instead of the
traditional dichotomy-innovators creating biotechnological products
and users passively purchasing and employing the products-thought
leaders in synthetic biology foresee a proliferation of synthetic biology
''user-innovators" designing and producing innovative products
outside the traditional formal laboratory setting historically
associated with conventional biotechnology. 277

273.
See
We
Are
Synthetic
Biology:
Management
Team,
DNA2.0,
https://www.dna20.com/company#1 (last visited Apr. 6, 2014).
274.
Author's personal communication with Claes Gustafsen, a founder of DNA2.0.
Id.
275.
276.
We Are Synthetic Biology: History, DNA2.0, https://www.dna20.com/company#2 (last
visited Apr. 6, 2014).
277.
See Hilgartner, supra note 270, at 200. User-innovators have sometimes been
referred to as "prosumers," whom Hilgartner describes as "individuals who engage
simultaneously in the production and consumption of value, like the masses of internet users
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As advances in synthetic biology lower the entry barrier for
innovators, it is envisioned that an increasing amount of the
innovation in synthetic biology will spring out of the garages of
do-it-yourself genetic engineers and hobbyists. 278 Expanding the pool
of potential participants in synthetic biology opens the door to
accelerated innovation, resulting not only in more synthetic biology
products than would be created by traditional companies and
academic institutions, but also quite likely fundamentally different
products, some examples of which are provided below.
The Biobricks Foundation (BBF), founded by a group of
synthetic biologists affiliated with the Massachusetts Institute of
Technology (MIT) and other universities, is attempting to facilitate
the democratization of synthetic biology by encouraging the
development and dissemination of what it refers to as "standardized
biological parts." 2 79 A standard biological part is a DNA sequence of
defined structure and function designed to share a common interface
such that multiple standard biological parts can be combined in a
manner that is both technically facile and functionally predictable. 280
The goal is to enable synthetic biologists to design relatively complex
genetic circuits comprising an arrangement of standard biological
parts, and then simply order the parts and assemble them in a
manner analogous to the way an electronic engineer might order
electronic parts in order to build an electronic circuit. 281
The MIT Registry of Standard Biological Parts has put the
ideals of the BBF into practice. The Registry maintains a collection of
standard biological parts that conform to the BBF standards of
predictability and interchangeability.
The catalog of standard
biological parts made available by the Registry includes DNA
sequences that encode full-length proteins or protein domains, as well
as various genetic regulatory elements such as promoters, reporters,
and receptors. 282 These standard biological parts are catalogued and
can be ordered and assembled by synthetic biologists to create novel
genetic constructs. The Registry allows synthetic biologists to focus on
who produce Web 2.0 content." Id. (citing George Ritzer & Nathan Jurgenson, Production,
Consumption, Prosumption: The Nature of Capitalism in the Age of the Digital "Prosumer",10 J.
CONSUMER CULTURE 13, 14 (2010)).

278.
See Jon Mooallem, Do-It-Yourself Genetic Engineering, N.Y. TIMES, Feb. 10, 2010,
http://www.nytimes.com/2010/02/14/magazine/14Biology-t.html.
279.
About, BIOBRICKS FOUNDATION, http:/Ibiobricks.org/about-foundation/ (last visited
Apr. 6, 2014).
280.
See Our Philosophy, IGEM, http://parts.igem.org/Help:Philosophy (last visited Apr.
6, 2014).
281.
See id.
282.
See Registry of Standard Biological Parts, IGEM, http://parts.igem.org/MainPage?
title=MainPage (last visited Apr. 6, 2014).
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genetic design without having to worry about synthesis of its
Significantly, users of the Registry's standard
constituent DNA.
biological parts are encouraged to contribute any new standard
biological parts that they develop back to the Registry, in order to
enrich the catalog and serve as the basis for further innovation by
other users.
The International Genetically Engineered Machine competition
(iGEM) provides a striking exemplar of the ideal of synthetic biology
and
by amateurs
conceived
and implemented
innovation
non-professionals. iGEM began in 2004 as a competition between five
teams of undergraduates representing MIT, Caltech, the University of
Texas, Princeton, and Boston University. 283 Their assignment was to
design and build "genetically encoded finite state machines using
standard, interchangeable biological parts." The University of Texas
team, for example, developed the world's first biological photograph
film, comprised of a lawn of synthetically engineered bacteria. 284
In 2005, the competition began accepting international teams,
and over the years the competition has continued to grow-by 2012, it
included 245 teams from around the globe, competing in five regional
events dispersed across the Americas, Europe, and Asia, and
culminating in a World Championship Jamboree held in Cambridge,
Massachusetts. 2 8 5 In 2011, iGEM was expanded to include not only
collegiate teams, 2 8 6 but also teams comprising high school students.
An Entrepreneurship Division was added to the competition in
2012.287

Today, each team competing in iGEM is provided with an
assortment of "biological parts"-i.e., DNA encoding useful genetic
elements, such as protein-encoding genes and various regulators of
genetic expression-provided by the Registry. Team members are
responsible for conceiving, designing, and synthesizing a synthetic
biological system, and introducing it into a living organism.2 8 8
Leveraging the power of synthetic biology, these teams of amateurs
have successfully developed a number of novel and innovative
synthetic biology products, ranging from whimsical to potentially
highly functional products.
283.
Synthetic Biology Based on Standard Parts, IGEM, http://igem.org/About (last
visited Apr. 6, 2014).
284.
Summer Competition-UT Austin, IGEM, http://2004.igem.org/austin.cgi (last
visited Apr. 6, 2014).
285.
See Synthetic Biology Based on Standard Parts, supra note 283; see also Jamborees,
IGEM, http://2012.igem.org/Jamborees (last visited Apr. 6, 2014).
286.
See Synthetic Biology Based on Standard Parts,supra note 283.
287.
See iGEME 2012, IGEM, http://2012e.igem.org (last visited Apr. 6, 2014).
288.
See Synthetic Biology Based on Standard Parts, supra note 283.
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For example, the overall winner of the 2012 collegiate
competition was a team representing the University of Groningen that
engineered a strain of bacteria to produce colored pigment when
exposed to the volatile compounds given off by spoiling meat. 2 89 The
team named its synthetic bacteria "Food Warden." The Groningen
team was inspired to produce the Food Warden by the disturbing
statistic that 1.3 billion tons of food is thrown away every year,
partially as a result of the ubiquitous "best before" dating system, and
that much of the discarded food is not actually spoiled. 290 The team
developed a packaging system to safely position the bacteria next to a
meat product in order to alert a consumer if meat has gone bad, while
assuring them that they do not have to throw away meat that has
exceeded its "best before" date but has actually not spoiled.
Other notable iGEM projects have included a bacterial arsenic
biosensor created by a 2006 team representing the University of
Edinburgh. The Edinburgh team was attempting to respond to a need
in many underdeveloped countries, particularly Bangladesh, for a
more economical, portable, and easier to use product for detecting
arsenic contamination in water.2 91
In 2011, a team from the
University of Washington developed a synthetic strain of E. coli
bacteria capable of producing diesel fuel, and a synthetic protease
engineered to catalyze the breakdown of gluten in the digestive track
when taken in pill form. 29 2

While the iGEM competition has given birth to a number of
potentially highly useful products, the creativity of the teams can
often take a whimsical turn. For example, in 2009, Team Osaka's
entry was a petri dish full of genetically engineered, glow-in-the-dark
bacteria arranged to detect the famous Nintendo videogame hero
Mario. 293 The use of engineered biological organisms as a medium of
artistic expression is becoming quite popular, with a website called
"Microbial Art" dedicated to its encouragement and display. 294 In
short, user-innovation in synthetic biology is coming to resemble the
289.
See Jamborees, supra note 285.
290.
See Abstract, IGEM, http://2012.igem.org/Team:Groningen/Project (last visited Apr.
6, 2014).
291.
See Edinburgh Summary Page: Summary of the Arsenic Biosensor Project, IGEM,
http://2006.igem.org/wikilindex.php/Edinburgh-summary-page (last visited Apr. 6, 2014);
University of Edinburgh 2006, IGEM, http://2006.igem.org/University of Edinburgh_2006 (last
visited Apr. 6, 2014).
292.
See Make It or Break It: Diesel Production and Gluten Destruction, the Synthetic
Biology Way, IGEM, http://2011.igem.org/Team:Washington (last visited Apr. 6, 2014).
293.
See Eric Fernandez, Japanese CreateFluorescentMario from Genetically Engineered
Bacteria, BIO 4 BEGINNERS (Mar. 23, 2010, 1:14 PM), http://diybio4beginners.blogspot.com/
2010/03/japanese-create-fluorescent-mario-from_25.html.
294.
Welcome, MICROBIAL ART, http://www.microbialart.com/ (last visited Apr. 6, 2014).
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user-innovation that has developed on the Internet, ranging from the
highly practical to playful.
Significantly, the BBF, Registry, and iGEM all strive to foster
an ethos of openness and collaboration. The Registry attempts to
ensure that its parts are not encumbered by IP or other usage
restrictions, and encourages its users to reciprocate by contributing
newly developed standard biological parts back to the Registry
without restriction.
Participants in the iGEM competition are
specifically required to contribute any standard biological part they
develop back to the Registry as a prerequisite to having their project
considered by the judges. 295
Synthetic biology innovation by amateurs is also being fostered
by the establishment of open laboratories that allow anyone with an
interest in synthetic biology to come in and, for a modest fee, design,
manufacture, and test their own DIY synthetic biology projects. For
example, in the San Francisco Bay area, an organization called
BioCurious has opened a community biotechnology laboratory where
interested amateurs learn the techniques of synthetic biology and use
them to create their own products. 296 A similar community biolab
called Genspace was opened in New York City in December 2010.297
According to their web page, "Genspace was founded by a group of
science enthusiasts who come from different professions-artists,
engineers, writers and biologists. Unlike traditional institutions, our
diversity is our strength and the source of our innovation." 298
One striking aspect of the rise of user-innovators and
do-it-yourselfers in synthetic biology has been the embrace of
large-scale collaboration and openness.
The development of
conventional biotechnology products has generally been a proprietary
process, conducted by independent biotechnology companies that have
jealously guarded their secrets and IP. In contrast, much of the
excitement in synthetic biology centers around the prospect of
collaborative design and product development.
Biocurious, for
example, has created a "hackerspace" where users can come together
to share ideas and collaborate on projects. 299 They are currently
sponsoring two community projects, open to anyone, which seek to

295.
Requirements, IGEM, http://2013.igem.org/Requirements (last visited Apr. 6, 2014).
296.
See BioCurious-The World's First Hackerspace for Biotech, Located in Silicon
Valley, BioCURIOUS, http://biocurious.org/ (last visited Apr. 6, 2014).
297.
See About, GENSPACE, http://genspace.org/page/About (last visited Apr. 6, 2014).
298.
Id.
299.
About, BIOCURIOUS, http://biocurious.org/about/ (last visited Apr. 6, 2014).
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foster a collaborative approach to advancing the implementation of
bioluminescence and bioprinting. 300
One communal synthetic biology project that has garnered
significant attention recently, dubbed "Glowing Plant," is attempting
to engineer plants that give off light. 301

Glowing Plant is being

conducted by a collaborative group of synthetic biology hobbyists who
used the website Kickstarter to obtain funding. 302 The goal of the
project is not only to potentially provide a technology to reduce our
dependence on electricity for lighting, but also to publicize DIY
synthetic biology and "inspire others to create new living things." 303
V. THE EMERGING IP IMPERATIVES OF SYNTHETIC BIOLOGY

For a variety of reasons, it seems likely that the current IP
regime will prove less effective at protecting and incentivizing
innovation in synthetic biology than it has been for conventional
biotechnology. On the one hand, limitations of the patent system,
such as its high cost and long delays in patent issuance, will generally
more severely than conventional
impact synthetic biologists
biotechnology firms. On the other hand, third-party patents might
create crippling freedom to operate issues for synthetic biologists, a
fear voiced by Professor Endy at the "IP Law and the Biosciences
Conference" at Stanford University. 304 Freedom to operate issues
could be particularly problematic for user-innovators and DIY
At the same time, the relatively modest
synthetic biologists.
regulation of synthetic biology products will reduce the pseudo-IP
barrier to competitor entry that currently benefits conventional
biotechnology companies marketing innovative drugs and agricultural
products, while the ease with which many synthetic biology inventions
can be reversed engineered will limit the effectiveness of trade secret
law. These and other failures of the current IP regime to satisfy the
imperatives of synthetic biology are the subject of this Part.

300.
BioCurious Projects, BIOCURIOUS, http://biocurious.org/projects/ (last visited Apr. 6,
2014).
301.
See Andrew Pollack, A Dream of Trees Aglow at Night, N.Y. TIMES, May 7, 2013,
http://www.nytimes.com/2013/05/08/business/energy-environment/a-dream-of-glowing-trees-isassailed-for-gene-tinkering.html?pagewanted=all&_r=1&.
Growing Plant: Natural Lighting Without Electricity, GLOWING PLANT,
302.
http://glowingplant.com/ (last visited Apr. 6, 2014). Kickstarter is an internet-based funding
platform for project creators to post their idea, set a funding goal, and place a deadline for
reaching their funding goal. Seven Things to Know About Kickstarter, KICKSTARTER,
https://www.kickstarter.com/hello (last visited Apr. 6, 2014). Those funding goals must be met for
creators to receive any money. Id.
303.
Pollack, supra note 301.
See Endy, supra note 1, at 42:54-45:02.
304.
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A. The Tread Toward Weaker Patent Protectionfor Biotechnology
Conventional biotechnology companies benefited from a
relatively permissive standard of patentability, as established by
decisions such as Chakrabarty, Wands, and Deuel. In recent years,
however, the courts have raised the bar to some extent, a trend that
could have some impact on synthetic biology companies. In particular,
tightening the standards of patentability limits the ability of
companies to patent two important categories of innovation in
synthetic biology: engineered DNA sequences and algorithms used in
the design of genetic sequences.
The Lilly and Kubin decisions, for example, appeared to signal
a retreat from earlier decisions widely interpreted as having
established a very permissive standard for the patenting of newly
isolated DNA molecules. The full import of the Supreme Court's
recent decision in Myriad awaits clarification in the lower courts, but
the case appears to primarily implicate the patentability of DNA and
other biomolecules purified from a natural source, or having a
chemical structure identical, or at least highly similar, to a naturally
occurring counterpart. 305 As the products of synthetic biology continue
to diverge further and further from natural biology, the impact of
these decisions on synthetic biology should be relatively modest.
Kubin, for example, seems to merely stand for the reasonable
proposition that the same standard of nonobviousness should apply to
DNA-based inventions as does to non-DNA inventions. And while
Lilly initially appeared to create a serious impediment to the
patenting of DNA in general, including wholly synthetic DNA,
subsequent interpretation of the doctrine by the Federal Circuit has
greatly blunted its effect, and many extremely broad DNA and
biotechnology patent claims have successfully withstood challenges to
validity based on the Lilly written description requirement.3 06
Some of the most important synthetic biology inventions are
algorithms used to design synthetic genes and genetic systems.
DNA2.0, for example, has developed proprietary algorithms used for
designing DNA sequences optimized in a variety of ways to
satisfy the performance requirements of their customers.3 07 Perhaps
unfortunately for companies investing in the development of these
algorithms, the availability of effective patents for useful algorithms

305.
See Memorandum from Andrew H. Hirshfeld, Deputy Commissioner for Patent
Examination Policy, U.S. Patent & Trademark Office, to Patent Examining Corps 1 (Mar. 4,
2014), available at http://www.uspto.gov/patents/law/exam/myriad-mayo-guidance.pdf.
306.
See Holman, supra note 117, at 78-79.
307.
Products, DNA2.0, https://www.dna20.com/products (last visited Apr. 6, 2014).
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was cast into serious doubt by the Supreme Court's recent decision in
Bilski v. Kappos.308 The Court in Bilski found the business method
claims at issue in that case were patent ineligible because they
encompassed what the Court characterized as "abstract ideas," a label
which might arguably apply to algorithms used in synthetic biology. 309
Moreover, even if a synthetic biology company succeeded in
claiming an algorithm in terms that satisfy the strictures of Bilski, it
still faces the Catch-22 presented by patent law's requirement that an
algorithm must be disclosed in order to be patented. In particular, full
disclosure of the algorithm will often be necessary in order to satisfy
the enablement, written description, or definiteness requirements. 3 10
Once the algorithm has been publicly disclosed, the patent might be of
little practical value if a competitor can learn the algorithm from the
patent and proceed to use it in a manner that cannot be detected by
the patent owner, e.g., as an internal process shielded from public
view. Furthermore, even if use of the algorithm can be detected and
proven, the patent will not be infringed if the use occurs outside the
United States in a jurisdiction in which the algorithm has not been
patented, or in a country, such as China or India where enforcement of
patents often proves challenging for US companies.3 1
B. The Cost, Delay, and Uncertainty of Patent Protection
To the extent synthetic biology companies seek to
commercialize a larger number of products than conventional
biotechnology companies, albeit with a decreased expectation of
profitability for each individual product, the high cost of obtaining a
patent could become more of an issue for these companies than it has
been for conventional biotechnology. It typically costs somewhere in
the neighborhood of $10,000 or more to obtain a US patent, and
substantially more if protection outside the United States is also
desired.3 12 For a conventional biotechnology company developing what

308.
Bilski v. Kappos, 561 U.S. 593 (2010).
309.
See id. at 609-12.
310.
See, e.g., Aristocrat Techs. Austl. PTY Ltd. v. Int'l Game Tech., 521 F.3d 1328, 1338
(Fed. Cir. 2008) (holding patent invalid for lack of definiteness because it did not disclose
required algorithms used for machine to function, and a person of ordinary skill in the art would
not find any algorithm disclosed in the patent).
311.

See U.S.

PATENT & TRADEMARK OFFICE, REPORT ON PATENT ENFORCEMENT IN

&

CHINA 1-2 (2012), available at http://www.uspto.gov/ip/global/ChinaReport-onPatent
Enforcement_(FullRprt)FINAL.pdf.
312.
See Gene Quinn, The Cost of Obtaining a Patent in the US, IPWATCHDOG (Jan 28,
2011, 1:14 PM), http://www.ipwatchdog.com/2011/01/28/the-cost-of-obtaining-patent/id=14668/;
see also WORLD INTELLECTUAL PROP. ORG., PCT FEE TABLES (2014), available at
http://www.wipo.int/export/sites/www/pct/en/fees.pdf, PCT Fees in US Dollars, U.S. PAT.
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it hopes will become a blockbuster product, the cost of obtaining
patents is relatively modest relative to the potential profitability of
the product. On the other hand, for the more marginally profitable
products envisioned under the synthetic biology paradigm, the cost of
obtaining a patent could become a much more significant concern.
The problem is greatly compounded in an environment where the
company has numerous products in its research and development
pipeline for which some form of IP protection is deemed necessary to
prevent harmful competition by free riders, but projected profits
simply do not justify the cost of patenting.
The recently enacted America Invents Act (AIA) has very likely
substantially increased the cost of patenting by expanding the range
of post-grant procedures available by which third-parties can oppose
issued patents. 313
Not only will these procedures burden
cash-strapped synthetic biology companies with the cost of responding
to post-grant challenges as they arise, they also tend to devalue
patents by weakening the presumption of validity traditionally
associated with issued US patents. 314
While obtaining and maintaining patent protection is
expensive, the costs pale in comparison with the cost of patent
enforcement. Patent litigation is a notoriously expensive undertaking,
typically costing hundreds of thousands, or even millions, of dollars
just to complete discovery, and much more if the case proceeds to
judgment. 315 For a blockbuster conventional biotechnology product,
the price of patent litigation can be justified by the huge amount of
revenue at stake. However, for a modestly profitable synthetic biology
product, the cost might very well render patent enforcement
impractical.
The long lag time between the filing of a patent application and
patent issuance might also create a comparatively greater problem for
a synthetic biology company than it has for conventional biotechnology
companies. As discussed above, synthetic biology products are likely
to reach the market faster than conventional biotechnology products,
but they are also likely to have a shorter commercial life. As a

TRADEMARK OFF., http://www.uspto.gov/patents/init-events/pet/sample/fees.jsp (last modified
Dec. 12, 2014).
313.
Post Grant Review, U.S. PAT. & TRADEMARK OFF., http://www.uspto.gov/
aia implementation/faqs-postgrant review.jsp (last visited Apr. 6, 2014).
314.
See Gene Quinn, Prominent Independent Investors Unhappy with Innovation Act,
IPWATCHDOG (Nov. 20, 2013, 2:56 PM), http://www.ipwatchdog.com/2013/11/20/prominentindependent-inventors-unhappy-with-innovation-act/id=46436/.
315.
See Jim Kerstetter, How Much Is That Patent Lawsuit Going to Cost You?, CNET
(Apr. 5, 2012, 10:00 AM), http://news.cnet.com/8301-32973-3-57409792-296/how-much-is-thatpatent-lawsuit-going-to-cost-youl.
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consequence, the delay in patent protection will likely expose
innovative synthetic biology companies to pre-patent product launches
and subsequent competition from free riding copycats. A patent that
does not issue until near the end of a product's commercial life
provides little benefit to the patent owner. Significantly, Paul Michel,
former Chief Judge of the Court of Appeals for the Federal Circuit, has
opined that today, the greatest problem with the patent system and
the biggest deterrent to US innovation is the excessive delay to receive
a patent. 316
The unpredictability and uncertainty of patent law might also
have a disproportionately adverse impact on synthetic biology
companies. As discussed above, conventional biotechnology companies
have largely dealt with the problem by throwing money at it, a
feasible strategy for a company focused on the development of a small
number of potential blockbuster products. For a typical synthetic
biology company that anticipates less profitability on a per product
basis, less money will be available to invest in developing a patent
portfolio resilient to the unpredictability of patent law for each
proposed product. A synthetic biology company might even decide not
to pursue patent protection for its inventions if it concludes that the
uncertainty with respect to the availability of effective patent
protection is such that it is not worth the substantial investment of
time and money.
To the extent these various limitations on the patent system
conspire to deprive synthetic biology innovators of effective IP
protection for their innovations, it could discourage synthetic biology
companies from engaging in the sort of beneficial disaggregated
product development process described above. While collaboration
and outsourcing would improve the efficiency of product development,
innovative companies will be reluctant to engage in such activities if
they fear that collaborating third parties might copy their innovations.
With patents, or patent applications, solidly in place, a company can
have some confidence that it will be able to share its proprietary
technology
and know-how
without opening
itself up to
misappropriation. In the absence of patents, the company might be
forced to rely on contractual restrictions or trade secret law, both of
which provide more limited protection than the exclusive right to the
patent owner. Faced with this choice, a rational company might
conclude that it is too risky to outsource aspects of the product
development process, and instead decide to perform all the necessary
316.
Interview by Intellectual Prop. Watch with Judge Paul R. Michel, Chief Judge, U.S.
Court of Appeals for the Fed. Circuit (July 14, 2011), available at http://www.ipwatch.org/2011/07/14/interview-with-chief-judge-paul-r-michel-on-us-patent-reform/.
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tasks internally, even if this means forgoing some of the important
benefits that can flow from a more collaborative approach to synthetic
biology.
C. Freedom to Operate Concerns
For a variety of reasons, it seems likely that synthetic biology
companies will have a harder time dealing with freedom to operate
issues created by third-party patents than has been the experience of
conventional biotechnology companies. For one thing, the increasing
complexity of the products made possible by synthetic biology will tend
to implicate more third-party patents, particularly as the technology
moves from relatively straightforward genetic constructs involving
only a small number of genes to much more elaborate systems
comprising a relatively large number of genes and intricate regulatory
networks. The increasing number of individual genetic constituents,
as well as sub-combinations of those elements, will likely expand the
universe of patents that need to be addressed in assessing freedom to
operate with respect to any given product development proposal. The
larger number of discrete products projected for synthetic biology
companies further amplifies freedom to operate concerns.
Freedom to operate decisions are influenced by the projected
profitability of a product, since the decision to move forward on a
project often hinges on weighing the likely benefit to be gained from
proceeding with the project against the cost and risk of potential
patent infringement.
For a conventional biotechnology company
seeking to develop a blockbuster product, the ultimate outcome of any
product development project is likely to be either complete failure or
overwhelming success.
In the case of failure, infringement of
third-party patents is largely a moot point, since failed products rarely
attract infringement lawsuits. On the other hand, if the company does
succeed in bringing a blockbuster product to market, the huge profits
will normally outweigh even a relatively high risk of infringing a
third-party patent. In contrast, under the synthetic biology paradigm,
there is a higher probability of a company bringing a product to
market that is successful enough to provoke the threat of an
infringement lawsuit, yet not profitable enough to justify the cost of
defending against such a suit. Consequently, a rational synthetic
biology company might be less inclined than a conventional
biotechnology company to move forward with the development of a
potentially infringing product.
The specialization and division of labor to which synthetic
biology aspires could also exacerbate freedom to operate issues for
some synthetic biology companies. Synthetic biology service providers
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and other intermediaries in collaborative product development, such
as DNA synthesis or DNA assembly companies or providers of
biological parts, like the Registry of Standard Biological Parts, could
become focal points for infringement liability; given the difficulty of
determining freedom to operate with respect to the thousands of
genetic elements these entities might be expected to provide for a
diverse set of customers and collaborators. Firms such as these will in
many cases not even be involved in the design of DNA sequences they
are asked to produce, and will have little idea of the patent landscape
surrounding the sequences. Given the limited profitability associated
with the manufacture and sale of any given genetic sequence, even a
relatively low perceived threat of infringement liability could dampen
a service provider's enthusiasm for taking on a project.
For example, the Registry has adopted a policy of only
providing standard biological parts to academic, non-commercial
users, largely out of fear that providing biological parts to commercial
companies could expose the Registry to infringement liability. 3 17 This
is an unfortunate state of affairs because resources such as those
provided by the Registry could play a crucial role in facilitating the
synthetic biology revolution, freeing engineers to focus their energies
on the design of synthetic genetic systems while outsourcing the
actual DNA synthesis to specialists. The Presidential Commission for
the Study of Bioethical Issues recently noted that access to
standardized, modular biological parts, such as those provided by the
Registry, will be especially critical if synthetic biology is to develop to
its full potential, and stressed the importance of fostering an IP
regime that allows for this access. 318
The unpredictability of patent law, and the resulting general
uncertainty regarding claim interpretation and validity, is also likely
to create more freedom to operate concerns for synthetic biology
companies than it has for conventional biotechnology companies. For
reasons discussed above, synthetic biology companies are likely to be
more risk-averse and less likely to proceed with the project if there is
any possibility of being sued for patent infringement, even if an
objective analysis of the patent claims predicts a high likelihood that
the claims are either invalid or would not be infringed. Amateur
synthetic biologists and user-innovators, unable to afford legal counsel
and not anticipating large profits from their creations, might be

317.
E-mail from Randy Rettberg, President, iGEM, to Christopher M. Holman,
Professor of Law, Univ. of Mo.-Kansas City Sch. of Law (Aug. 8, 2013, 13:02 CST) (on file with
author).
318.
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particularly reluctant to engage in activities that seem to pose even a
remote likelihood of infringement liability.
It has often been the practice to claim a biotechnology
invention in relatively broad terms that cover not only embodiments of
the invention specifically envisioned by the inventor, but also a wide
array of functional analogues. For example, a biotechnology inventor
who develops a protein with certain useful functional attributes might
be able to obtain a patent with claims that purport to broadly cover
other proteins sharing those same functional attributes, or any DNA
molecule encoding such a protein.3 1 9 Such a patent might create
freedom to operate issues for a synthetic biologist who independently
engineers a novel protein that happens to share the claimed functional
attribute. The freedom to operate issues presented by broad claims of
this type are exacerbated by uncertainty in claim interpretation.3 2 0
D. Reduced Regulation of Synthetic Biology Products Will Increase the
Importance of Other Forms of IP
As discussed
above,
strict government regulation
of
conventional biotechnology products can constitute an effective
non-patent impediment to competitor market entry.
The less
intensive regulatory oversight of a typical synthetic biology product
could render patent protection-or some other alternative to patents,
such as copyright, as discussed below-critical for synthetic biology
companies hoping to capture the value of their investment in
innovation.
The lower regulatory hurdle to commercialization for synthetic
biology products will increase the importance of patent claim scope for
synthetic biology companies. Even a very narrow claim covering a
conventional biotechnology product, like a drug or agricultural trait,
can be extremely effective if it is buttressed by substantial regulatory
barriers to market entry by competitors. A potential competitor is
limited in its ability to design around the patent claims, because even
a relatively minor structural change to a biologic product can have
significant functional consequences, and as a result, a company
seeking to achieve regulatory approval for a modified version of a
product will be unable to leverage the data generated and used by the
innovator to secure marketing approval for its product. 321
For
example, the new abbreviated approval process for biologics is only
available for follow-on products that are "biosimilar" to the innovator's

319.
320.
321.

Id. at 120.
See Holman, supra note 138, at 662-63.
See supra Part II.C.
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product, which necessitates relatively close structural similarity
between the follow-on and innovative products. 322
In contrast, for a less strictly regulated synthetic biology
product, it will be much less necessary for a follow-on competitor to
rely on the innovator's regulatory approval in order to gain market
entry. 323 A potential follow-on competitor will thus have greater
leeway to redesign its product in a manner that avoids the innovator's
patents. 324 It will thus be important for synthetic biology companies
to obtain patents that not only cover their specific product, but that
also broadly cover alternatives that might otherwise be used to design
around the patent. Unfortunately, recent developments in patent law,
particularly the Lilly written description requirement and the PTO's
implementation of that requirement, have rendered it more difficult to
achieve a broad scope of protection for biotechnology inventions. 325
Absent the availability of broad patent rights, non-patent IP and
quasi-IP will become increasingly important to adequately incentivize
advances in synthetic biology.
E. The Ease of Reverse EngineeringLimits the Utility of Trade Secret
in ProtectingSynthetic Biology Innovation
The most important products of conventional biotechnology,
protein drugs, are difficult to copy. The process and reagents used in
making a protein drug cannot be reverse engineered from the product,
and even a competitor with detailed information regarding how an
innovator company produces a drug will have difficulty replicating the
process. As described above, "the product is the process" when it
comes to biologics. 326
Even innovators sometimes have trouble
reproducing their own processes when they try to scale them up or
relocate to a new facility. 327 Successfully introducing an agricultural
trait into a viable crop seed is also a technically challenging
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Biologics Price Competition and Innovation Act of 2009 § 7002, 42 U.S.C. §262
(2012).
323.
See Christopher M. Holman, Protein Similarity Score: A Simplified Version of the
Blast Score as a Superior Alternative to PercentIdentity for Claiming Genuses of Related Protein
Sequences, 21 SANTA CLARA COMPUTER & HIGH TECH. L.J. 55, 61 (2004). It is possible to generate
gene and protein variants with substantially modified structures that retain the function of the
original gene or protein. Id. at 59.
324.
See id. at 61.
325.
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undertaking requiring a great deal of know-how and empirical
experimentation.
But synthetic biology is refining the tools and methodology for
manipulating DNA to a point where even amateurs and hobbyists can
construct synthetic DNA molecules and organisms. Powerful new
technologies for sequencing and synthesizing DNA are rendering it a
fungible product and will make it increasingly feasible to successfully
reverse engineer synthetic biology products. The ease with which
synthetic biology inventions can be reverse engineered will severely
undercut the ability of synthetic biology companies to use trade secret
law to protect their investments in innovation, since it is
well-established that reverse engineering a product does not
constitute misappropriation of a trade secret. 328
F. The Susceptibility of Synthetic Biology Products to Viral Copying
Increases the Importance of IP
The necessity of effective IP protection for synthetic biology is
exacerbated by the inherent susceptibility of many of these products to
viral replication and copying. As pointed out more than forty years
ago by the National Commission on New Technological Uses of
Copyrighted Works (CONTU), the underlying principle behind IP is
that "if the cost of duplicating information is small, then it is simple
for a less than scrupulous person to duplicate it. . . . [L]egal as well

as physical protection for the information is a necessary incentive if
such information is to be created and disseminated." 329 Although at
the time, CONTU was specifically addressing the need of effective IP
protection for computer programs, today the ease with which
engineered DNA and organisms can be duplicated renders the
statement equally applicable to synthetic biology.
The ease in which engineered DNA can be the subject of
unauthorized copying is readily apparent in the realm of agricultural
biotechnology.
Most of the important genetically modified seed
types-including soybean, canola, and cotton-can be saved and
replanted with the progeny retaining the benefits of the engineered

328.
2003).
329.

See, e.g., Kadant, Inc. v. Seeley Machine, Inc., 244 F. Supp. 2d 19, 37-38 (N.D.N.Y.
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should be protected under copyright law. See Pamela Samuelson, CONTU Revisited: The Case
Against Copyright Protection for Computer Programs in Machine-Readable Form, 1984 DUKE
L.J. 663, 665 (1984).

VAND.

452

J. ENT. & TECH. L.

[Vol. 17:2:385

trait. 330 Some have gone so far as to characterize genetically modified
seeds as "self-replicating" technology because of the ease with which
any farmer in possession of the seeds can use them as the template for
the production of a virtually unlimited number of perfect copies. 331 Ip
protection is absolutely crucial for self-replicating products such as
these, because without it, progeny seeds could be replanted,
eliminating the need for farmers to pay for the technology after an
initial growing season and significantly weakening the value of an
agricultural biotechnology company's patents. 332
Fortunately, the Supreme Court's recent decision in Bowman v.
Monsanto Co. clarified that the sale of a patented product comprising
genetically engineered DNA does not exhaust patent rights with
respect to progeny seed. 333 If the Court had ruled otherwise, the
decision might have had serious negative implications not only for
agricultural biotechnology, but also more generally for synthetic
biology. 334 Many of the products of synthetic biology are easily
replicable and thus highly susceptible to unauthorized appropriation
and free riding in the absence of effective IP protection. For example,
synthetic organisms used in the synthesis of chemicals or as
biosensors can be easily replicated, and once an innovator company
loses control of even a small sample of the organism, it can be copied,
re-copied, and disseminated widely to unauthorized users. In fact, a
self-replicating synthetic biology product can be as vulnerable to viral
replication and widespread distribution as digitally recorded music
"shared" over the Internet. 335
The ease with which many synthetic biology inventions can be
copied, the fungibility of genetic sequence information, and the overall
increased efficiency and predictability of synthetic biology all tend to
render effective IP protection especially important for synthetic
biology companies. In its absence, companies might turn to non-IP
mechanisms for capturing value, such as technological restrictions on
copying. For example, agricultural biotechnology companies could
introduce genetic use restriction technologies (GURTs) to deter

330.
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(No. 11-796), 2012 U.S. S. Ct. Briefs LEXIS 5142.
332.
Brief of Holman, supra note 191, at 31-32.
333.
See Bowman v. Monsanto Co., 133 S. Ct. 1761, 1766-67 (2013).
Brief of Holman, supranote 191, at 5.
334.
335.
Id. at 28-30.

2015]

DEVELOPMENTS IN SYNTHETIC BIOLOGY

453

unauthorized copying. 336 In contrast with patents, a GURT would
never expire, so in some ways, a move away from patents could result
in increased restrictions on access to the technology compared to a
patent-based model of value capture.
Another way that a synthetic biology innovator might address
a perceived inadequacy of available IP protection would be for the
company to retain physical control over all copies of a proprietary
synthetic organism. In agriculture, certain pineapple growers who
have developed new pineapple varieties and only allow the variety to
be grown in fields controlled by the company have adopted this
approach. 337 The US District Court for the Southern District of
Florida has held that a pineapple company that took this approach to
protecting its proprietary pineapple varieties could also legally protect
the genetics of the pineapples under trade secret law. 338 A synthetic
biology company might very well adopt an analogous approach as an
alternative to patent protection.
For example, a synthetic biology company that has produced a
synthetic organism for making a high value chemical, such as a drug,
could use the organism in-house to produce the drug and maintain
strict controls over access to the organism. Only the drug product
would be released to the public, and access to the drug would not
provide the necessary information to reverse engineer the organism.
Trade secret law would generally be available to assist the innovator
in protecting against misappropriation of the organism by a competing
company.339
G. Some Attributes of Synthetic Biology that Will Attenuate the
Importance of IP
While the susceptibility of engineered DNA to viral replication
will increase the importance of Ip,340 other aspects of synthetic biology
will tend to attenuate the need for strong IP protection. For one thing,
synthetic biology companies generally will be able to bring products to
market quicker and cheaper than conventional biotechnology
companies, and as a consequence, they will be less dependent upon the
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large infusions of investment capital that were the lifeblood of
companies like Genentech and Amgen. DNA2.0, for example, has
never relied on venture capital investment. 341 The company was
initially funded through the personal savings and credit of its
founders, but within months the company was selling synthetic DNA
to customers and thereby was able to start selling products and
generating revenue. 342 To the extent a synthetic biology company can
operate without substantial outside investment, a strong IP position is
not as critical to success as it has been for conventional biotechnology
companies.
As described above, synthetic biology companies have been able
to take advantage of grant funding from governmental and
non-governmental agencies, such as the Defense Advanced Research
Projects Agency (DARPA) or the Bill & Melinda Gates Foundation. 343
Funding agencies of this type are primarily interested in the public
benefit to be derived from the synthetic biology projects they fund, 344
rather than a return on investment, and thus IP is not as much of a
concern for them as it would be for a venture capitalist investor.
The increasingly relevant role of user-innovators and amateur
synthetic biologists will also reduce the importance of IP. These
individuals are less likely than conventional biotechnology companies
to feel the need to exclude others from copying and building upon their
innovations. Some of their synthetic biology projects will have little
utilitarian function, as exemplified by the microbial artworks
discussed above. Others will be aimed at addressing the needs of the
developing world, such as the arsenic biosensor built by the University
of Edinburgh students, 345 not at generating a profit. In any event,
patents are of little value when the users of a product cannot afford to
pay for it or enforce it and, in fact, might be viewed as nothing more
than obstacles to the desired widespread adoption of the technology.
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VI. ADAPTING INTELLECTUAL PROPERTY TO THE IMPERATIVES OF
SYNTHETIC BIOLOGY

There are several reforms and modifications of the current IP
regime that might render it better suited to satisfy the imperatives of
synthetic biology. To begin with, not only synthetic biology, but the
entire innovator community would benefit from any reforms that
would improve the predictability and certainty of patent law,
particularly with respect to the requirements of patentability, patent
scope and patent enforcement. In fact, in recent years the courts and
Congress have introduced a number of reforms that have significantly
reduced the role of subjective, intent-based doctrines of patent law,
and these reforms should do something to help with the
unpredictability. 346 For example, Congress has effectively eliminated
the best mode requirement, a subjective element of US patent law that
contributed to the uncertainty with respect to claim validity. 347 The
Federal Circuit has also introduced some needed reforms-for
example, by raising the bar for proving the intent necessary to
establish subjective states of mind such as "willful infringement" and
"inequitable conduct." 348
Unfortunately, in recent years, the Supreme Court has
overruled a number of attempts by the Federal Circuit to increase the
clarity of US patent law. The recent patent-eligibility rulings by the
Supreme Court-Bilski, Mayo, and Myriad-stand as prime
examples. 349 Congress could potentially intervene, but much of the
unpredictability has to do with substantive requirements of
patentability like patent-eligibility, enablement, written description,
and obviousness, and the experience from the most recent round of
patent reform legislation suggests that Congress has no appetite for
addressing the substance of these doctrines. It seems that the high
degree of unpredictability in patent law will be with us for the
foreseeable future.
It also seems unlikely that the high cost of obtaining a patent
will abate anytime soon. A large percentage of the cost of obtaining a

346.
See Robert A. Armitage, Understanding the America Invents Act and Its
Implicationsfor Patenting, 40 AIPLA Q.J. 1, 14 (2012).
347.
See Leahy-Smith America Invents Act, Pub. L. No. 112-29, § 15(b), 125 Stat. 284,
328 (enacting conforming amendment that strikes the best mode requirement of 35 U.S.C. §§
119(e)(1), 120).
348.
See, e.g., Therasense v. Becton, Dickinson & Co., 649 F.3d 1276, 1290 (Fed. Cir.
2011); In re Seagate Tech., LLC, 497 F.3d 1360, 1371 (Fed. Cir. 2007).
349.
See Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2111
(2013); Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1297 (2012); Bilski
v. Kappos, 561 U.S. 593, 605 (2010).
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patent arises from the fees charged by a patent practitioner to
prepare, file, and prosecute the application. Given the complexity of
the process and the highly specialized expertise necessary to do it
correctly, the cost of preparing and prosecuting a quality patent
application is likely to remain high. One possible mechanism for
reducing the cost is by off-shoring some of the process, such as the
drafting of the specification, to countries like India.3 50 However, this
means of cost-saving comes with attendant risk and could backfire on
a company that finds that in order to save a few thousand dollars, it
has lost its ability to obtain effective patent protection owing to a
poorly drafted application. 351
Part of the cost of obtaining a patent arises out of the fees
charged by the PTO-here is where meaningful reform could have
some impact. For years, much of the fees paid by patent applicants to
the PTO have been diverted to other federal programs outside the
patent office. 352
Commentators refer to this practice as a tax on
innovation that is "sap[ping] the lifeblood of the American economy"
by increasing the cost innovators must pay to obtain patent protection,
while at the same time harming the quality and expediency of the
patent examination process. 35 3 In 2011, Senator Coburn attempted to
introduce an amendment to the AIA that would have ended the
practice of fee diversion, but the amendment failed by a small
margin. 354 Although some initially believed that provisions of the AIA
would be sufficient to put an end to fee diversion, in April 2013, the
practice was resumed under the auspices of sequestration.
It is widely believed that fee diversion has substantially
contributed to delays in patent examination and issuance.
For
example, a Report of the National Academy of Public Administration
estimates the current backlog of unexamined patent applications is
the direct result of fee diversion. 355 The Report estimates that if the
350.
See Joel R. Merkin, Litigating Outsourced Patents: How Offshoring May Affect the
Attorney-Client Privilege, 2006 U. Ill. J.L. TECH. & POL'Y 215, 215 (2006).
351.
See id. at 217.
352.
See Sen. Tom Coburn, Patent Fee Diversion Is a Tax on Innovation, NAT'L REV.
ONLINE (Sept. 6, 2011),http://www.nationalreview.com/corner/276344/patent-fee-diversion-taxinnovation-sen-tom-coburn.
Id.
353.
354.
Press Release, Sen. Tom Coburn, Senate Votes to Protect the Diversion
of Patent Fees (Sept. 8, 2011), available at http://www.coburn.senate.gov/publiclindex.cfm/
pressreleases?ContentRecord-id=b46eleb6-d7c2-4810-9f6f-9c362e3738ae&ContentType-id=
d741b7a7-7863-4223-9904-8cb9378aaO3a&Groupid=41cf7e93-d82e-44c6-b4fb-f686b568e689;
Joshua Nightingale, Patent Reform Fails to Halt Fee Diversion, INVENTORS DIG. (Dec. 16, 2011),
http://www.inventorsdigest.com/archives/7664.
355.
See NAT'L ACAD. OF PUB. ADMIN., U.S. PATENT AND TRADEMARK OFFICE:
TRANSFORMING TO MEET THE CHALLENGES OF THE 21ST CENTURY, at xx (2005), available at

http://www.napawash.org/images/reports/2005/05USPatentandTrademarkOffice.pdf.
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PTO had not been subjected to fee diversion, the application pendency
time would have averaged slightly over twenty-one months, as
compared with the thirty to forty months that it currently takes to
process a patent application. 356 Synthetic biology would benefit
greatly if Congress would take the necessary steps to prevent fee
diversion, allowing the PTO to invest all of its users' fees to improve
the quality and timeliness of patent examination.
Patent office delays can have inordinately adverse effects on
certain applicants and applications, and to address this concern, PTO
regulations define a number of categories of applications that can be
designated "special" and thereby eligible for expedited examination. 357
In some cases, synthetic biology companies could no doubt avail
themselves to this regulatory fast track. For example, special status
is available under circumstances where US manufacture of a product
covered by a pending application is imminent or where actual
infringement is occurring, and this status could obviously benefit a
synthetic biology company finding itself in one of these situations.
There are also some technology specific categories that could
find a specific applicability with respect to synthetic biology
companies.
For example, the regulations specifically authorize
special status for applications directed towards inventions
which would "materially (i) [e]nhance the quality of the environment
[or] (ii) [clontribute to the development or conservation of
energy resources . . . ."358 Special status is also available for patent
applications relating to HIV/AIDS and cancer and for inventions that
materially contribute to countering terrorism.35 9 These categories all
represent subject matter currently being targeted by synthetic biology,
and companies seeking patents in these areas should consider availing
themselves to the expedited examination program.
In fact, there are two biotechnology-specific categories of
subject matter eligible for special status that might benefit some
synthetic biology companies. One of these provides special status for
"biotechnology applications" filed by small entities, 360 and the other for
"patent applications relating to safety of research in the field of
recombinant DNA." 3 6 1 Unfortunately, restrictions on these categories
could limit their usefulness to synthetic biology companies.
In
particular, an expedited path for "biotechnology applications" is not
356.
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357.
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available for larger companies ineligible for small entity status, and
the "recombinant DNA" category is limited to inventions relating to
research safety. Very little synthetic biology patenting is likely to
involve research safety, and thus this exception for recombinant DNA
will likely not be very relevant for synthetic biology companies.
The United States is currently considering the creation of the
equivalent of a "small claims court" for patent litigation, 362 which
might address the problem posed for synthetic biology by the high cost
of patent enforcement. The idea is not a new one-England has had
such a court for twenty years, limited to claims for relief no greater
than 500,000 pounds. 363 A patent small claims court for the United
States was proposed by the AIPLA nearly twenty years ago and has
been endorsed by the ABA and AIPLA, but has yet to receive
congressional support. 364 However, responding to the concern that the
cost of patent litigation has made patent enforcement largely
inaccessible in cases where likely damages are not at least $1 million,
in December 2012, the PTO issued a notice seeking public comments
on a proposal to institute such a court in the United States. 365 The
time for comments ended last spring, and momentum is reportedly
building toward the creation of such a court, a development that could
substantially benefit synthetic biology companies.366
VII. COULD COPYRIGHT PLAY A ROLE IN SYNTHETIC BIOLOGY?

For decades, the extension of copyright protection to genetically
engineered DNA has been debated, but until now, the idea has failed
to gain significant traction. In contrast, after some initial skepticism,
the extension of copyright to software was embraced in the 1980s and
the consensus seems to be that it has provided important incentives
for innovation without many of the negative consequences attendant
to patent protection. 367
Given the striking analogy between
362.
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DAILY (May 8, 2013), available at http://www.bna.com/key-players-update-n17179873839/.
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engineered DNA and software, and the fact that both technologies
came into prominence around the same time, it seems incongruous
that the two forms of engineered "code" are treated so differently
under copyright law. Much of the explanation might lie in the fact
that in the early days of software there was a general sense that
software was not patentable subject matter, and copyright was
recruited to fill the gap.36 8 In contrast, the 1980 Chakrabartydecision
was seen as signaling the viability of patent protection for
conventional biotechnology, 36 9 creating the perception that an
extension of copyright to engineered DNA was unnecessary.
In a recent law review article, I explained why, as a doctrinal
matter, some form of engineered DNA should probably be considered
copyrightable, largely based on the analogy and growing convergence
of software and engineered DNA. 3 70 Synthetic biologists have been
discussing the idea, but a clear consensus has yet to emerge. In his
presentation at Stanford Law School, Professor Endy opined that
"given the history in software, there is going to be for the foreseeable
future an ever-renewing enthusiasm for exploring the idea of
copyright" for synthetic biology. 3 7 1 He noted that "literally every
student I see . . . who connects with property rights immediately

presumes that you should be treating this stuff like code, and they are
familiar with using copyright in that context." 37 2 However, Endy went
on to caution that while the expansion of copyright to DNA might
"naively [be] immediately attractive" because the transaction cost of
establishing copyright is "tasty compared to a patent claim," this use
of copyright could be "horrifying" and "really dangerous if you mess it
up" because copyright protection of a particular product will "never
end." 37 3 Perhaps significantly, aside from his concern about copyright
duration, Professor Endy offered no further substantive basis for
concern regarding copyright of DNA. 3 7 4
Although the idea of open source biotechnology is certainly
appealing, and there have been some attempts to implement it, the
role of open source in real-world biotechnology has been minimal at
best. For example, one commentator recently pointed out that while
the BBF espouses the ethos of open source, its user agreement lacks
368.
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"self-perpetuating copyleft restrictions on the disposition of entities
containing the parts, [and as a consequence] cannot prevent
next-generation creations assembled using BioBrick parts from
escaping its control. The result is a regime that tightly controls
existing parts in ways that enforce openness but exerts no similar
control over next-generation parts, except to the extent that Users
voluntarily decide to become Contributors of their new parts." 375
One potential advantage of extending copyright to engineered
DNA might be that it would facilitate the viability of true open source
synthetic biology. Copyright law is the IP foundation upon which
software open source has been built, and it has proven difficult to
transpose the principles of open source on a biotechnology IP regime
dominated by patents and contractual restraints. 376 Copyright plays
an important role in assuring that open-source software remains
freely to be used and improved by others, while maintaining proper
attribution for original creative contributions. 3 7 7
There would be other advantages in using copyright as an
alternative to patents for the protection of synthetically engineered
DNA. For one thing, it would address concerns with the cost and
delay associated with patent procurement.
An original work of
copyrightable expression receives copyright protection the moment it
is "fixed in any tangible medium of expression." 378 There is no need to
take any affirmative steps to secure copyright protection, although
registration with the Copyright Office does provide substantial
benefits to the copyright owner and is generally a prerequisite to
judicial enforcement against an infringer.
On the other hand, copyright generally provides a much
narrower scope of protection than does patent law. As applied to
software, for example, copyright does not protect algorithms or other
functional aspects of a computer program, but rather is limited to the
specific code employed in a particular program. 379 Copyright prevents
others from directly copying a protected work, thus providing an
important means for fighting piracy, but it does not extend to
independently created works, no matter how closely they might
resemble the original copyrighted work.38 0
Importantly, since
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copyright is limited to original works, it should not be available for
naturally occurring DNA sequences, 381 thus avoiding many of the
policy concerns associated with gene patents that were brought to the
public's attention by the Myriad case. These and other positive
attributes of copyright law are discussed at more length in a
previously published article on DNA copyright. 382
It bears noting that the logic of Myriad would seem to argue in
The plaintiffs
favor of extending copyright to engineered DNA.
emphasized the unique informational role of DNA, which they argued
distinguishes it from other chemical compounds, and the Supreme
Court, along with some judges in the lower courts, seemed to adopt
this view, pointing to the informational aspect of isolated DNA
The
as a significant factor in assessing its patent-eligibility. 3 8 3
informational quality of DNA tends to support its analogy to computer
software and other copyrightable subject matter. It also provides a
rational basis for limiting copyright to DNA, rather than opening the
door to copyright protection for any man-made chemical compound.
A former Monsanto patent counsel recently shared an
interesting anecdote regarding the applicability of copyright to
engineered DNA. 3 8 4 During a recent visit to an Indian Patent Office,
the attorney was discussing the patenting of engineered DNA, and one
of the Indian patent examiners voiced his opinion that copyright is a
more appropriate form of IP protection for engineered DNA than
patents. This patent examiner, working in a country that is relatively
hostile towards patents, particularly in the context of biotechnology,
had come to the same conclusion as have proponents of DNA copyright
in this country-it just makes sense. It is time to seriously consider
extending copyright to engineered DNA.
Or if that idea is too
revolutionary, we should at least be considering some sui generis form
of IP protection for DNA that embodies some of the positive attributes
of copyright.38 5
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VIII. CONCLUSION

A patent-centric approach to IP, at times bolstered by
regulatory barriers to market entry and trade secret law, has for the
most part proven sufficient to incentivize innovation in conventional
biotechnology. But the changing paradigm brought about by the
synthetic biology revolution is altering the equation, creating new
imperatives that will strain the capacity of the current IP regime.
While certain reforms to the patent system have been
instituted-such as an end to fee diversion, improved access to
accelerated examination process, and the creation of a patent small
claims court-more drastic measures might be in order. New modes of
IP for engineered DNA should be seriously considered, particularly
some form of copyright, or perhaps a sui generis protection that
embodies positive aspects of copyright law. Such an expansion of our
conception of IP for engineered DNA might spur innovation in
synthetic biology in the same manner that Chakrabarty did with
respect to conventional biotechnology.

